adalimumab vs adalimumab-adbm (Cyltezo)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Crohn's Disease

Shared mechanism: TNF-alpha · full Crohn's Disease pipeline

adalimumab · Humira

Marketed by AbbVie and partners

Approved in Crohn's Diseasemonoclonal antibody (fully human IgG1)
Partial signal

NCT00055497 · Phase 3 · completed

Design meets top-tier criteria (randomized, quadruple-blind, placebo-controlled, hard clinical endpoint), but the randomized comparison population was very small (only 55 total randomized participants across 3 arms) and the two primary analysis methods gave discordant significance results (NRI missed, LOCF met), which per the definitions caps this at moderate under both the underpowered-n and mixed/unclear-primary-result tests.

Next expected readout: June 2027 · NCT06045754 (registry estimate)

Reported efficacy

Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4: Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4 (Week 4): Double-Blind Period, Weeks 0 to 4: Placebo 6.8% vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg 37.3%; p=<0.001 (Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg) (met)

Result source: NCT02499783

adalimumab-adbm (Cyltezo)

Marketed by Boehringer Ingelheim

Approved in Crohn's Diseasemonoclonal antibody
Reliable signal

NCT02871635 · Phase 3 · completed

This was a randomized, double-blind trial against the reference adalimumab product, with a validated Crohn's disease activity score as the primary endpoint. Clinical response at week 4 was similar in both groups (risk ratio 0.945, 90% CI 0.870 to 1.028), within the prespecified non-inferiority margin, and 147 people were randomized against a planned 130.

Hanauer et al. (Lancet Gastroenterol Hepatol, 2021; PMID 34388360) report different figures for this outcome, clinical response in 61 of 68 patients (90%) with BI 695501 and 68 of 72 (94%) with the reference product, because the registry figures are model-based least-squares means.

Reported efficacy

Percentage of Patients With a Clinical Response (CDAI Decrease of ≥70 Compared With Baseline) at Week 4: Clinical response (CDAI decrease of 70 points or more) at week 4, BI 695501 vs Humira (modified full analysis set): 61/68 (90%) vs 68/72 (94%); adjusted risk ratio 0.945 (90% CI 0.870 to 1.028), lower limit above the exploratory non-inferiority margin of 0.76 (Hanauer 2021, Lancet Gastroenterol Hepatol). (met)

Result source: NCT02871635

Results for Crohn's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumabadalimumab-adbm (Cyltezo)
Clinical remission (induction)37.3% vs 6.8%+30.5 vs placebo160/80 mg · wk 4 · n 102NCT02499783
1 other result
  • 46.9% vs 27.7% wk 12 · n 64 · Phase 3 · secondary NCT00348283
—Not reported
Endoscopic response (induction)—Trial running · NCT05040464—Not reported
Clinical remission (maintenance)38.1% vs 9.1%+29 vs placebo40 mg Eow · wk 52 · n 21NCT00445432
11 other results
  • 47.4% vs 33.3% 40 mg every other week · wk 56 · n 19 · Phase 3 · primary NCT00055497
  • 66.7% vs 33.3% 40 mg every week · wk 56 · n 18 · Phase 3 · primary NCT00055497
  • 78.9% vs 44.4% 40 mg every other week · wk 56 · n 19 · Phase 3 · primary NCT00055497
  • 83.3% vs 44.4% 40 mg every week · wk 56 · n 18 · Phase 3 · primary NCT00055497
  • 36.3% vs 38.9% 40 mg every other week · wk 24 · n 204 · Phase 3 · secondary NCT00055497
  • 40.2% vs 38.9% 40 mg every other week · wk 24 · n 204 · Phase 3 · secondary NCT00055497
  • 32.8% vs 9.2% wk 52 · n 64 · Phase 3 · secondary NCT00348283
  • 57.9% vs 38.9% 40 mg every other week · wk 24 · n 19 · Phase 3 · secondary NCT00055497
  • 94.4% vs 38.9% 40 mg every week · wk 24 · n 18 · Phase 3 · secondary NCT00055497
  • 57.9% vs 38.9% 40 mg every other week · wk 24 · n 19 · Phase 3 · secondary NCT00055497
  • 94.4% vs 38.9% 40 mg every week · wk 24 · n 18 · Phase 3 · secondary NCT00055497
68.6% vs 76.2%vs Humira EUwk 24 · n 68NCT02871635
Endoscopic response (maintenance)—Trial running · NCT05040464—Not reported

Clinical remission (induction)

adalimumab
37.3% vs 6.8%+30.5 vs placebo160/80 mg · wk 4 · n 102NCT02499783
1 other result
  • 46.9% vs 27.7% wk 12 · n 64 · Phase 3 · secondary NCT00348283
adalimumab-adbm (Cyltezo)
—Not reported

Endoscopic response (induction)

adalimumab
—Trial running · NCT05040464
adalimumab-adbm (Cyltezo)
—Not reported

Clinical remission (maintenance)

adalimumab
38.1% vs 9.1%+29 vs placebo40 mg Eow · wk 52 · n 21NCT00445432
11 other results
  • 47.4% vs 33.3% 40 mg every other week · wk 56 · n 19 · Phase 3 · primary NCT00055497
  • 66.7% vs 33.3% 40 mg every week · wk 56 · n 18 · Phase 3 · primary NCT00055497
  • 78.9% vs 44.4% 40 mg every other week · wk 56 · n 19 · Phase 3 · primary NCT00055497
  • 83.3% vs 44.4% 40 mg every week · wk 56 · n 18 · Phase 3 · primary NCT00055497
  • 36.3% vs 38.9% 40 mg every other week · wk 24 · n 204 · Phase 3 · secondary NCT00055497
  • 40.2% vs 38.9% 40 mg every other week · wk 24 · n 204 · Phase 3 · secondary NCT00055497
  • 32.8% vs 9.2% wk 52 · n 64 · Phase 3 · secondary NCT00348283
  • 57.9% vs 38.9% 40 mg every other week · wk 24 · n 19 · Phase 3 · secondary NCT00055497
  • 94.4% vs 38.9% 40 mg every week · wk 24 · n 18 · Phase 3 · secondary NCT00055497
  • 57.9% vs 38.9% 40 mg every other week · wk 24 · n 19 · Phase 3 · secondary NCT00055497
  • 94.4% vs 38.9% 40 mg every week · wk 24 · n 18 · Phase 3 · secondary NCT00055497
adalimumab-adbm (Cyltezo)
68.6% vs 76.2%vs Humira EUwk 24 · n 68NCT02871635

Endoscopic response (maintenance)

adalimumab
—Trial running · NCT05040464
adalimumab-adbm (Cyltezo)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. adalimumab: 4 of 4 rows · adalimumab-adbm (Cyltezo): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumabadalimumab-adbm (Cyltezo)
Dropout rate
—40 mg every other weeka
NCT00055497 · Phase 3
show 34 more results
15.8%40 mg every other week
NCT00055497 · Phase 3
11.1%40 mg every week
NCT00055497 · Phase 3
—40 mg every week
NCT00055497 · Phase 3
40.7%40 mg
NCT00055497 · Phase 3
—160/80 mg
NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3
48.5%
NCT00195715 · Phase 3
16.9%40 mg every other week or every week
NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3
4.4%
NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3
6.8%Induction: Higher Induction Dose
NCT02065570 · Phase 3 · monotherapy
6.8%Induction: Standard Induction Dose
NCT02065570 · Phase 3 · monotherapy
—Maintenance: Clinically Adjusted (
NCT02065570 · Phase 3 · monotherapy
—Maintenance: Therapeutic Drug Mana
NCT02065570 · Phase 3 · monotherapy
—Maintenance: Therapeutic Drug Moni
NCT02065570 · Phase 3 · monotherapy
21.4%
NCT02185014 · Phase 3 · monotherapy
61%
NCT00686374 · Phase 3 · monotherapy
—40 mg or 20 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—20 mg or 10 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
60%40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy
34.4%40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy
3%160 mg/80 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—160 mg/80 mg + 40/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—160 mg/80 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—80/40 mg + 40/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
5.9%80 mg/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
35.7%80 mg
NCT01958827 · Phase 3 · monotherapy
16.4%40 mg every other week
NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3
70.9%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
36%
NCT02148718 · Phase 4 · registry result, not featured evidence
26.7%Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
26.7%Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
25%BI 695501
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
show 2 more results
—BI 695501 (Baseline - Week 24 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
—BI 695501 (Week 24 - Week 46 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
Discontinued due to AEs
—40 mg every other weeka
NCT00055497 · Phase 3
show 34 more results
5.3%40 mg every other week
NCT00055497 · Phase 3
5.6%40 mg every week
NCT00055497 · Phase 3
—40 mg every week
NCT00055497 · Phase 3
12.7%40 mg
NCT00055497 · Phase 3
—160/80 mg
NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3
15.7%
NCT00195715 · Phase 3
6%40 mg every other week or every week
NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3
1.5%
NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3
3.9%Induction: Higher Induction Dose
NCT02065570 · Phase 3 · monotherapy
2.4%Induction: Standard Induction Dose
NCT02065570 · Phase 3 · monotherapy
—Maintenance: Clinically Adjusted (
NCT02065570 · Phase 3 · monotherapy
—Maintenance: Therapeutic Drug Mana
NCT02065570 · Phase 3 · monotherapy
—Maintenance: Therapeutic Drug Moni
NCT02065570 · Phase 3 · monotherapy
7.1%
NCT02185014 · Phase 3 · monotherapy
8%
NCT00686374 · Phase 3 · monotherapy
—40 mg or 20 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—20 mg or 10 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
4%40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy
21.9%40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy
3%160 mg/80 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—160 mg/80 mg + 40/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—160 mg/80 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—80/40 mg + 40/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
5.9%80 mg/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
10.7%80 mg
NCT01958827 · Phase 3 · monotherapy
10.9%40 mg every other week
NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3
16.4%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
—
NCT02148718 · Phase 4 · registry result, not featured evidence
20%Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
20%Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
5.6%BI 695501
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
show 2 more results
—BI 695501 (Baseline - Week 24 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
—BI 695501 (Week 24 - Week 46 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
Serious AEs
5.3%40 mg every other weeka
NCT00055497 · Phase 3
show 34 more results
—40 mg every other week
NCT00055497 · Phase 3
—40 mg every week
NCT00055497 · Phase 3
0%40 mg every week
NCT00055497 · Phase 3
16.7%40 mg
NCT00055497 · Phase 3
2%160/80 mg
NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3
38.1%
NCT00195715 · Phase 3
—40 mg every other week or every week
NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3
14.8%
NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3
4.5%Induction: Higher Induction Dose
NCT02065570 · Phase 3 · monotherapy
4.9%Induction: Standard Induction Dose
NCT02065570 · Phase 3 · monotherapy
4.6%Maintenance: Clinically Adjusted (
NCT02065570 · Phase 3 · monotherapy
6.4%Maintenance: Therapeutic Drug Mana
NCT02065570 · Phase 3 · monotherapy
—Maintenance: Therapeutic Drug Moni
NCT02065570 · Phase 3 · monotherapy
10.7%
NCT02185014 · Phase 3 · monotherapy
48%
NCT00686374 · Phase 3 · monotherapy
23.7%40 mg or 20 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
20%20 mg or 10 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
8%40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy
40.6%40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy
—160 mg/80 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—160 mg/80 mg + 40/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—160 mg/80 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—80/40 mg + 40/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—80 mg/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
28.6%80 mg
NCT01958827 · Phase 3 · monotherapy
—40 mg every other week
NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3
10.9%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
2.3%
NCT02148718 · Phase 4 · registry result, not featured evidence
—Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
6.7%Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
7.7%Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
6.7%Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
14.3%Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—BI 695501
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
show 2 more results
8.3%BI 695501 (Baseline - Week 24 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
2.8%BI 695501 (Week 24 - Week 46 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
Most frequent reported AEs
40 mg every other weeka
nasopharyngitis 26.3% (placebo 38.9%)
crohn's disease aggravated 21.1% (placebo 27.8%)
sinusitis 21.1% (placebo 5.6%)
NCT00055497 · Phase 3
show 28 more results
40 mg every week
crohn's disease aggravated 11.1% (placebo 27.8%)
dizziness (excl vertigo) 11.1% (placebo 5.6%)
nasopharyngitis 11.1% (placebo 38.9%)
NCT00055497 · Phase 3
40 mg
crohn's disease aggravated 17.6% (placebo 27.8%)
nasopharyngitis 16.7% (placebo 38.9%)
headache 14% (placebo 11.1%)
NCT00055497 · Phase 3
160/80 mg
white blood cell count decreased 5.9% (placebo 1%)
cough 4.9% (placebo 0%)
dizziness 3.9% (placebo 0%)
NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3
crohn's disease 39.8%
nasopharyngitis 26.1%
arthralgia 24.7%
NCT00195715 · Phase 3
40 mg every other week or every week
headache 18.9%
nasopharyngitis 14.4%
arthralgia 7.6%
NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3
crohn's disease 23.4% (placebo 29.2%)
headache 14.1% (placebo 9.2%)
nasopharyngitis 14.1% (placebo 12.3%)
NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3
nasopharyngitis 6.2%
headache 5.5%
crohn's disease 4.5%
NCT02065570 · Phase 3 · monotherapy
headache 8.7%
arthralgia 7.8%
nausea 7.3%
NCT02065570 · Phase 3 · monotherapy
crohn's disease 14.7%
nasopharyngitis 13.8%
headache 8.3%
NCT02065570 · Phase 3 · monotherapy
crohn's disease 13.8%
nasopharyngitis 9.2%
headache 7.3%
NCT02065570 · Phase 3 · monotherapy
crohn's disease 11.9%
arthralgia 7.1%
nausea 6%
NCT02185014 · Phase 3 · monotherapy
viral upper respiratory tract infection 39%
headache 37%
upper respiratory tract infection 31%
NCT00686374 · Phase 3 · monotherapy
40 mg or 20 mg every other week
headache 17.2%
crohn's disease 11.8%
nausea 10.8%
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
20 mg or 10 mg every other week
headache 21.1%
crohn's disease 15.8%
nasopharyngitis 11.6%
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
40 mg Eow
nasopharyngitis 56% (placebo 12%)
rhinorrhoea 16% (placebo 0%)
adverse drug reaction 12% (placebo 4%)
NCT00445432 · Phase 2/3 · monotherapy
40 mg Eow
nasopharyngitis 71.9% (placebo 12%)
adverse drug reaction 18.8% (placebo 4%)
iron deficiency anaemia 18.8% (placebo 0%)
NCT00445432 · Phase 2/3 · monotherapy
160 mg/80 mg + 40/40 mg
adverse drug reaction 11.1% (placebo 4.3%)
application site swelling 11.1% (placebo 0%)
blood creatine phosphokinase (at investigator's discretion) 11.1% (placebo 0%)
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
160 mg/80 mg
headache 9.1% (placebo 4.3%)
upper respiratory tract infection 9.1% (placebo 4.3%)
abdominal distension 6.1% (placebo 0%)
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
80/40 mg + 40/40 mg
headache 16.7% (placebo 4.3%)
abdominal distension 8.3% (placebo 0%)
abdominal pain 8.3% (placebo 4.3%)
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
80 mg/40 mg
injection site reaction 8.8% (placebo 8.7%)
malaise 8.8% (placebo 0%)
rhinorrhoea 8.8% (placebo 0%)
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
80 mg
nasopharyngitis 46.4%
rash 14.3%
headache 10.7%
NCT01958827 · Phase 3 · monotherapy
40 mg every other week
crohn's disease 16.1%
abdominal pain 7.6%
injection site reaction 7.6%
NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3
300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
arthralgia 18.2%
crohn's disease 16.4%
nasopharyngitis 10.9%
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
vomiting 7%
abdominal mass 5.8%
arthralgia 4.7%
NCT02148718 · Phase 4 · registry result, not featured evidence
Low Induction Dose
leukopenia 20%
pyrexia 13.3%
arthralgia 6.7%
NCT02015793 · Phase 2 · registry result, not featured evidence
Low Induction Dose
leukopenia 15.4%
animal bite 7.7%
aphthous stomatitis 7.7%
NCT02015793 · Phase 2 · registry result, not featured evidence
Standard Induction Dose
alanine aminotransferase increased 13.3%
aspartate aminotransferase increased 13.3%
abdominal pain 6.7%
NCT02015793 · Phase 2 · registry result, not featured evidence
Standard Induction Dose
mycobacterium tuberculosis complex test positive 14.3%
aspartate aminotransferase increased 7.1%
asthenia 7.1%
NCT02015793 · Phase 2 · registry result, not featured evidence
arthralgia 8.3%
respiratory tract infection 6.9%
crohn's disease 5.6%
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
show 1 more result
nasopharyngitis 6.9%
weight increased 4.2%
arthralgia 2.8%
NCT02871635 · Phase 3 · Crohn's Disease · phase 3

Notes

  1. aPopulation comparability has not been reviewed for 24 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab

Clinical Remission 14.3% (n=28) @ 4wk80 mg
responder rate · % of participants
No placebo or comparator arm
NCT01958827 · Phase 3 · monotherapy
show 80 more results
25% (n=28) @ 8wk80 mg
NCT01958827 · Phase 3 · monotherapy
28.6% (n=28) @ 12wk80 mg
NCT01958827 · Phase 3 · monotherapy
32.1% (n=28) @ 16wk80 mg
NCT01958827 · Phase 3 · monotherapy
35.7% (n=28) @ 20wk80 mg
NCT01958827 · Phase 3 · monotherapy
42.9% (n=28) @ 24wk80 mg
NCT01958827 · Phase 3 · monotherapy
35.7% (n=28) @ 28wk80 mg
NCT01958827 · Phase 3 · monotherapy
42.9% (n=28) @ 32wk80 mg
NCT01958827 · Phase 3 · monotherapy
39.3% (n=28) @ 36wk80 mg
NCT01958827 · Phase 3 · monotherapy
39.3% (n=28) @ 40wk80 mg
NCT01958827 · Phase 3 · monotherapy
42.9% (n=28) @ 44wk80 mg
NCT01958827 · Phase 3 · monotherapy
39.3% (n=28) @ 48wk80 mg
NCT01958827 · Phase 3 · monotherapy
35.7% (n=28) @ 52wk80 mg
NCT01958827 · Phase 3 · monotherapy
36.3% (n=204) @ 56wk*40 mg
NCT00055497 · Phase 3 · converted to % from 74 Participants as posted
45.6% (n=204) @ 56wk*40 mg
NCT00055497 · Phase 3 · converted to % from 93 Participants as posted
38.7% (n=93) @ 26wk40 mg or 20 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
33.3% (n=93) @ 52wk40 mg or 20 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
28.4% (n=95) @ 26wk20 mg or 10 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
23.2% (n=95) @ 52wk20 mg or 10 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
60% (n=55) @ 10wk300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
54.5% (n=55) @ 26wk300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
59.4% (n=609) @ 48wk
NCT00195715 · Phase 3
68.8% (n=462) @ 108wk
NCT00195715 · Phase 3
69.5% (n=272) @ 156wk
NCT00195715 · Phase 3
46.7% (n=15) @ 204wk
NCT00195715 · Phase 3
43.7% (n=206) @ 4wk
NCT02065570 · Phase 3 · monotherapy
43.5% (n=308) @ 4wk
NCT02065570 · Phase 3 · monotherapy
51.5% (n=206) @ 12wk
NCT02065570 · Phase 3 · monotherapy
62.3% (n=308) @ 12wk
NCT02065570 · Phase 3 · monotherapy
89.2% (n=65) @ 0wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 58 Participants as posted
84.6% (n=65) @ 4wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 55 Participants as posted
89.2% (n=65) @ 8wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 58 Participants as posted
81.5% (n=65) @ 12wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 53 Participants as posted
83.1% (n=65) @ 24wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 54 Participants as posted
80% (n=65) @ 36wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 52 Participants as posted
73.8% (n=65) @ 48wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 48 Participants as posted
75.4% (n=65) @ 60wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 49 Participants as posted
72.3% (n=65) @ 72wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 47 Participants as posted
70.8% (n=65) @ 84wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 46 Participants as posted
69.2% (n=65) @ 96wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 45 Participants as posted
69.2% (n=65) @ 108wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 45 Participants as posted
64.6% (n=65) @ 120wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 42 Participants as posted
61.5% (n=65) @ 144wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 40 Participants as posted
53.8% (n=65) @ 168wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 35 Participants as posted
47.7% (n=65) @ 192wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 31 Participants as posted
41.5% (n=65) @ 216wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 27 Participants as posted
40% (n=65) @ 240wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 26 Participants as posted
35.4% (n=65) @ 264wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 23 Participants as posted
26.2% (n=65) @ 288wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 17 Participants as posted
23.1% (n=65) @ 312wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 15 Participants as posted
12.3% (n=65) @ 336wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 8 Participants as posted
10.8% (n=65) @ 360wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 7 Participants as posted
1.5% (n=65) @ 384wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 1 Participants as posted
54.65% (n=86) @ 2wk
NCT02148718 · Phase 4 · registry result, not featured evidence
62.79% (n=86) @ 4wk
NCT02148718 · Phase 4 · registry result, not featured evidence
26.7% (n=15) @ 2wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
46.7% (n=15) @ 2wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
40% (n=15) @ 4wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 4wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
60% (n=15) @ 6wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
73.3% (n=15) @ 6wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
60% (n=15) @ 8wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 8wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 10wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 10wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
60% (n=15) @ 12wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
73.3% (n=15) @ 12wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
60% (n=15) @ 14wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
73.3% (n=15) @ 14wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
60% (n=15) @ 16wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
73.3% (n=15) @ 16wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
60% (n=15) @ 18wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
73.3% (n=15) @ 18wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 20wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 20wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 22wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 22wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 24wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 24wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 26wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 26wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
CR-100 57.9% (n=19) vs 38.9% (n=18) placebo @ 24wk40 mg every other week
responder rate · % of participants
Maintenance
NCT00055497 · Phase 3 · converted to % from 11 Participants as posted
show 11 more results
94.4% (n=18) vs 38.9% (n=18) placebo @ 24wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 17 Participants as posted
53.9% (n=204) vs 38.9% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 110 Participants as posted
47.4% (n=19) vs 33.3% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 9 Participants as posted
72.2% (n=18) vs 33.3% (n=18) placebo @ 56wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 13 Participants as posted
49.5% (n=204) vs 33.3% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 101 Participants as posted
57.9% (n=19) vs 38.9% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 11 Participants as posted
94.4% (n=18) vs 38.9% (n=18) placebo @ 24wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 17 Participants as posted
53.9% (n=204) vs 38.9% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 110 Participants as posted
47.4% (n=19) vs 33.3% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 9 Participants as posted
72.2% (n=18) vs 33.3% (n=18) placebo @ 56wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 13 Participants as posted
49.5% (n=204) vs 33.3% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 101 Participants as posted
CR-70 68.4% (n=19) vs 44.4% (n=18) placebo @ 24wk40 mg every other week
responder rate · % of participants
Maintenance
NCT00055497 · Phase 3 · converted to % from 13 Participants as posted
show 11 more results
94.4% (n=18) vs 44.4% (n=18) placebo @ 24wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 17 Participants as posted
60.3% (n=204) vs 44.4% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 123 Participants as posted
47.4% (n=19) vs 33.3% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 9 Participants as posted
72.2% (n=18) vs 33.3% (n=18) placebo @ 56wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 13 Participants as posted
53.9% (n=204) vs 33.3% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 110 Participants as posted
94.7% (n=19) vs 83.3% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 18 Participants as posted
94.4% (n=18) vs 83.3% (n=18) placebo @ 24wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 17 Participants as posted
70.6% (n=204) vs 83.3% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 144 Participants as posted
78.9% (n=19) vs 72.2% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 15 Participants as posted
88.9% (n=18) vs 72.2% (n=18) placebo @ 56wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 16 Participants as posted
72.1% (n=204) vs 72.2% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 147 Participants as posted
IBDQ 43.4 vs 29.9 placebo score @ 24wk40 mg every other week
absolute change · score
Maintenance
NCT00055497 · Phase 3
show 6 more results
51.9 vs 29.9 placebo score @ 24wk40 mg every week
NCT00055497 · Phase 3
33.9 vs 29.9 placebo score @ 24wk40 mg every other week
NCT00055497 · Phase 3
45.7 vs 24.7 placebo score @ 56wk40 mg every other week
NCT00055497 · Phase 3
45.2 vs 24.7 placebo score @ 56wk40 mg every week
NCT00055497 · Phase 3
36 vs 24.7 placebo score @ 56wk40 mg every other week
NCT00055497 · Phase 3
27.8 vs 1.8 placebo score @ 52wk40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy
Clinical Remission 37.3% (n=102) vs 6.8% (n=103) placebo @ 4wk160/80 mg
responder rate · % of participants
Induction
NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 1 more result
46.9% (n=64) vs 27.7% (n=65) placebo @ 12wk*
NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 30 Subjects as posted
CDAI 67.6% (n=102) vs 27.2% (n=103) placebo @ 4wk160/80 mg
responder rate · % of participants
Induction
NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3
IBDQ Remission 40.2% (n=102) vs 20.4% (n=103) placebo @ 4wk160/80 mg
responder rate · % of participants
Induction
NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Clinical Response 100 85.7% (n=272) @ 156wk
responder rate · % of participants
No placebo or comparator arm
NCT00195715 · Phase 3
Clinical Response 70 91.2% (n=272) @ 156wk
responder rate · % of participants
No placebo or comparator arm
NCT00195715 · Phase 3
Corticosteroid-free Clinical Remission 50% (n=16) @ 10wk300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
responder rate · % of participants
No placebo or comparator arm
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
show 4 more results
56.3% (n=16) @ 26wk300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
63.1% (n=103) @ 156wk
NCT00195715 · Phase 3
48% (n=100) @ 12wk
NCT02065570 · Phase 3 · monotherapy
52.9% (n=155) @ 12wk
NCT02065570 · Phase 3 · monotherapy
Steroid-free Clinical Response 100 74.8% (n=103) @ 156wk
responder rate · % of participants
No placebo or comparator arm
NCT00195715 · Phase 3
Fistula Remission 55.8% (n=43) @ 156wk
responder rate · % of participants
No placebo or comparator arm
NCT00195715 · Phase 3

+ 61 further endpoints in the CSV export.

adalimumab-adbm (Cyltezo)

CDAI ≥ 70 88% (n=68) vs 93.1% (n=72) Humira EU @ 4wk
responder rate · % of participants
Induction
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
CDAI ≥ 70 87.4% (n=68) vs 87.4% (n=72) Humira EU @ 24wk
responder rate · % of participants
Maintenance
NCT02871635 · Phase 3 · Crohn's Disease · phase 3

Ulcerative Colitis

Shared mechanism: TNF-alpha · full Ulcerative Colitis pipeline

adalimumab · Humira

Marketed by AbbVie and partners

Approved in Ulcerative Colitismonoclonal antibody (fully human IgG1)
Partial signal

NCT00385736 · Phase 3 · completed

Design is strong (randomized, quadruple-blind, placebo-controlled, n=576, hard endoscopic/clinical Mayo remission endpoint), but the primary endpoint result was discordant across the two pre-specified dose-vs-placebo comparisons: one significant, one not. A well-designed trial with a mixed result is capped at moderate rather than strong.

Next expected readout: September 2027 · NCT06257875 (registry estimate)

Reported efficacy

Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8; Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 52: Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8 (Week 8): Adalimumab 160/80/40 16.5% vs Placebo 9.3%; p=0.019 (Adalimumab 160/80/40 vs Placebo) (met)

Result source: NCT00408629

adalimumab-adbm (Cyltezo)

Marketed by Boehringer Ingelheim

Approved in Ulcerative Colitismonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumabadalimumab-adbm (Cyltezo)
Clinical remission (induction)10% vs 11.5%−1.5 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
6 other results
  • 13.8% vs 11.5% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · primary NCT00853099
  • 10% vs 9.2% 80/40 · wk 8 · n 130 · Phase 3 · primary NCT00385736
  • 18.5% vs 9.2% 160/80/40 · wk 8 · n 130 · Phase 3 · primary NCT00385736
  • 16.5% vs 9.3% 160/80/40 · wk 8 · n 248 · Phase 3 · primary NCT00408629
  • 10% vs 11.5% 160 mg/80 mg · wk 8 · n 90 · Phase 3 · secondary NCT00853099
  • 13.8% vs 11.5% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
—Not reported
Clinical remission (maintenance)20% vs 7.3%+12.7 vs placebo160 mg/80 mg · wk 52 · n 90NCT00853099
14 other results
  • 26.4% vs 7.3% 80 mg/40 mg · wk 52 · n 87 · Phase 3 · primary NCT00853099
  • 17.3% vs 8.5% 160/80/40 · wk 52 · n 248 · Phase 3 · primary NCT00408629
  • 29% vs 33.3% standard dose · wk 52 · n 31 · Phase 3 · primary NCT02065557
  • 45.2% vs 33.3% high dose · wk 52 · n 31 · Phase 3 · primary NCT02065557
  • 27.3% vs 33.3% standard dose · wk 52 · n 33 · Phase 3 · primary NCT02065557
  • 42.9% vs 33.3% high dose · wk 52 · n 35 · Phase 3 · primary NCT02065557
  • 20% vs 7.3% 160 mg/80 mg · wk 52 · n 90 · Phase 3 · secondary NCT00853099
  • 17.8% vs 8.3% 160 mg/80 mg · wk 32 · n 90 · Phase 3 · secondary NCT00853099
  • 26.4% vs 7.3% 80 mg/40 mg · wk 52 · n 87 · Phase 3 · secondary NCT00853099
  • 17.2% vs 8.3% 80 mg/40 mg · wk 32 · n 87 · Phase 3 · secondary NCT00853099
  • 42.9% vs 37.5% standard dose · wk 52 · n 21 · Phase 3 · secondary NCT02065557
  • 45.5% vs 37.5% high dose · wk 52 · n 22 · Phase 3 · secondary NCT02065557
  • 42.9% vs 37.5% standard dose · wk 52 · n 21 · Phase 3 · secondary NCT02065557
  • 44% vs 37.5% high dose · wk 52 · n 25 · Phase 3 · secondary NCT02065557
—Not reported
Clinical response (induction)50% vs 35.4%+14.6 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
4 other results
  • 42.5% vs 35.4% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
  • 54.6% vs 44.6% 160/80/40 · wk 8 · n 130 · Phase 3 · secondary NCT00385736
  • 51.5% vs 44.6% 80/40 · wk 8 · n 130 · Phase 3 · secondary NCT00385736
  • 50.4% vs 34.6% 160/80/40 · wk 8 · n 248 · Phase 3 · secondary NCT00408629
—Not reported
Endoscopic improvement (induction)44.4% vs 30.2%+14.2 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
2 other results
  • 39.1% vs 30.2% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
  • 41.1% vs 31.7% 160/80/40 · wk 8 · n 248 · Phase 3 · secondary NCT00408629
—Not reported
Corticosteroid-free remission (maintenance)13.3% vs 5.7%+7.6 vs placebo160/80/40 · wk 52 · n 150NCT00408629
5 other results
  • 13.3% vs 5.7% 160/80/40 · wk 52 · n 150 · Phase 3 · secondary NCT00408629
  • 30.8% vs 40% standard dose · wk 52 · n 13 · Phase 3 · secondary NCT02065557
  • 31.3% vs 40% high dose · wk 52 · n 16 · Phase 3 · secondary NCT02065557
  • 26.7% vs 40% standard dose · wk 52 · n 15 · Phase 3 · secondary NCT02065557
  • 35.3% vs 40% high dose · wk 52 · n 17 · Phase 3 · secondary NCT02065557
—Not reported

Clinical remission (induction)

adalimumab
10% vs 11.5%−1.5 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
6 other results
  • 13.8% vs 11.5% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · primary NCT00853099
  • 10% vs 9.2% 80/40 · wk 8 · n 130 · Phase 3 · primary NCT00385736
  • 18.5% vs 9.2% 160/80/40 · wk 8 · n 130 · Phase 3 · primary NCT00385736
  • 16.5% vs 9.3% 160/80/40 · wk 8 · n 248 · Phase 3 · primary NCT00408629
  • 10% vs 11.5% 160 mg/80 mg · wk 8 · n 90 · Phase 3 · secondary NCT00853099
  • 13.8% vs 11.5% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
adalimumab-adbm (Cyltezo)
—Not reported

Clinical remission (maintenance)

adalimumab
20% vs 7.3%+12.7 vs placebo160 mg/80 mg · wk 52 · n 90NCT00853099
14 other results
  • 26.4% vs 7.3% 80 mg/40 mg · wk 52 · n 87 · Phase 3 · primary NCT00853099
  • 17.3% vs 8.5% 160/80/40 · wk 52 · n 248 · Phase 3 · primary NCT00408629
  • 29% vs 33.3% standard dose · wk 52 · n 31 · Phase 3 · primary NCT02065557
  • 45.2% vs 33.3% high dose · wk 52 · n 31 · Phase 3 · primary NCT02065557
  • 27.3% vs 33.3% standard dose · wk 52 · n 33 · Phase 3 · primary NCT02065557
  • 42.9% vs 33.3% high dose · wk 52 · n 35 · Phase 3 · primary NCT02065557
  • 20% vs 7.3% 160 mg/80 mg · wk 52 · n 90 · Phase 3 · secondary NCT00853099
  • 17.8% vs 8.3% 160 mg/80 mg · wk 32 · n 90 · Phase 3 · secondary NCT00853099
  • 26.4% vs 7.3% 80 mg/40 mg · wk 52 · n 87 · Phase 3 · secondary NCT00853099
  • 17.2% vs 8.3% 80 mg/40 mg · wk 32 · n 87 · Phase 3 · secondary NCT00853099
  • 42.9% vs 37.5% standard dose · wk 52 · n 21 · Phase 3 · secondary NCT02065557
  • 45.5% vs 37.5% high dose · wk 52 · n 22 · Phase 3 · secondary NCT02065557
  • 42.9% vs 37.5% standard dose · wk 52 · n 21 · Phase 3 · secondary NCT02065557
  • 44% vs 37.5% high dose · wk 52 · n 25 · Phase 3 · secondary NCT02065557
adalimumab-adbm (Cyltezo)
—Not reported

Clinical response (induction)

adalimumab
50% vs 35.4%+14.6 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
4 other results
  • 42.5% vs 35.4% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
  • 54.6% vs 44.6% 160/80/40 · wk 8 · n 130 · Phase 3 · secondary NCT00385736
  • 51.5% vs 44.6% 80/40 · wk 8 · n 130 · Phase 3 · secondary NCT00385736
  • 50.4% vs 34.6% 160/80/40 · wk 8 · n 248 · Phase 3 · secondary NCT00408629
adalimumab-adbm (Cyltezo)
—Not reported

Endoscopic improvement (induction)

adalimumab
44.4% vs 30.2%+14.2 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
2 other results
  • 39.1% vs 30.2% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
  • 41.1% vs 31.7% 160/80/40 · wk 8 · n 248 · Phase 3 · secondary NCT00408629
adalimumab-adbm (Cyltezo)
—Not reported

Corticosteroid-free remission (maintenance)

adalimumab
13.3% vs 5.7%+7.6 vs placebo160/80/40 · wk 52 · n 150NCT00408629
5 other results
  • 13.3% vs 5.7% 160/80/40 · wk 52 · n 150 · Phase 3 · secondary NCT00408629
  • 30.8% vs 40% standard dose · wk 52 · n 13 · Phase 3 · secondary NCT02065557
  • 31.3% vs 40% high dose · wk 52 · n 16 · Phase 3 · secondary NCT02065557
  • 26.7% vs 40% standard dose · wk 52 · n 15 · Phase 3 · secondary NCT02065557
  • 35.3% vs 40% high dose · wk 52 · n 17 · Phase 3 · secondary NCT02065557
adalimumab-adbm (Cyltezo)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

adalimumab-adbm (Cyltezo): no structured comparison results are available for Ulcerative Colitis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. adalimumab: 4 of 4 rows · adalimumab-adbm (Cyltezo): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumab
Dropout rate
6.9%160/80/40a
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 18 more results
9.2%80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
37.6%160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
—Adalimumab Group - Double-Blind Pe
NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
52.5%
NCT02632175 · Phase 3 · monotherapy
—high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—open-label high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
10.3%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
12.4%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study): TDM Regi
NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
56.4%40 mg EOW/EW
NCT00573794 · Phase 3 · monotherapy
34.1%160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
33.3%80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
23.8%
NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Discontinued due to AEs
3.1%160/80/40a
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 18 more results
4.6%80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
5%160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
—Adalimumab Group - Double-Blind Pe
NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—
NCT02632175 · Phase 3 · monotherapy
—high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—open-label high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
3.3%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
3.4%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study): TDM Regi
NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
13.8%40 mg EOW/EW
NCT00573794 · Phase 3 · monotherapy
14.3%160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
10.3%80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
5.6%
NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Serious AEs
4%160/80/40a
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 18 more results
3.8%80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
12.1%Adalimumab Group - Double-Blind Pe
NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
27.1%
NCT02632175 · Phase 3 · monotherapy
7.8%high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
5.6%open-label high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
15.6%standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
13.9%high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
15.2%standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
3.8%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
5%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
12.6%Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
12.8%Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
9.9%Maintenance (Main Study): TDM Regi
NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
26.7%40 mg EOW/EW
NCT00573794 · Phase 3 · monotherapy
11.1%160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
16.1%80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
14.5%
NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Most frequent reported AEs
160/80/40a
colitis ulcerative 4% (placebo 3.6%)
fatigue 4% (placebo 2.2%)
headache 3.1% (placebo 7.2%)
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 17 more results
80/40
headache 6.9% (placebo 7.2%)
colitis ulcerative 5.4% (placebo 3.6%)
nasopharyngitis 4.6% (placebo 1.8%)
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
nasopharyngitis 17.5% (placebo 10.4%)
colitis ulcerative 16.3% (placebo 22.3%)
headache 8.6% (placebo 14.2%)
NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
colitis ulcerative 33.9%
upper respiratory tract infection 27.1%
nasopharyngitis 22%
NCT02632175 · Phase 3 · monotherapy
high dose
headache 9.8% (placebo 16.7%)
anaemia 5.9% (placebo 8.3%)
nausea 5.9% (placebo 0%)
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
open-label high dose
headache 22.2% (placebo 16.7%)
abdominal pain 11.1% (placebo 8.3%)
oropharyngeal pain 11.1% (placebo 0%)
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
standard dose
headache 12.5% (placebo 16.7%)
colitis ulcerative 6.3% (placebo 16.7%)
nasopharyngitis 6.3% (placebo 8.3%)
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
high dose
colitis ulcerative 11.1% (placebo 16.7%)
nasopharyngitis 11.1% (placebo 8.3%)
upper respiratory tract infection 11.1% (placebo 16.7%)
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
standard dose
headache 18.2% (placebo 16.7%)
c-reactive protein increased 9.1% (placebo 0%)
colitis ulcerative 9.1% (placebo 16.7%)
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
headache 8.4%
nasopharyngitis 5.1%
arthralgia 3.1%
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
headache 6.1%
colitis ulcerative 5.3%
nasopharyngitis 4.2%
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
colitis ulcerative 13.4%
nasopharyngitis 13.1%
arthralgia 6.6%
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
colitis ulcerative 17.4%
nasopharyngitis 13.6%
arthralgia 6.7%
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
colitis ulcerative 15.2%
nasopharyngitis 7.3%
upper respiratory tract infection 6%
NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
40 mg EOW/EW
colitis ulcerative 30.4%
viral upper respiratory tract infection 19.4%
arthralgia 10.5%
NCT00573794 · Phase 3 · monotherapy
160 mg/80 mg
nasopharyngitis 33.3% (placebo 21.9%)
iron deficiency anaemia 8.9% (placebo 7.3%)
headache 7.8% (placebo 6.3%)
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
80 mg/40 mg
nasopharyngitis 21.8% (placebo 21.9%)
injection site reaction 8% (placebo 2.1%)
dental caries 6.9% (placebo 5.2%)
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
colitis ulcerative 13.2%
headache 13%
nasopharyngitis 8%
NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3

Notes

  1. aPopulation comparability has not been reviewed for 2 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab

Clinical Remission 10% (n=90) vs 11.5% (n=96) placebo @ 8wk160 mg/80 mg
responder rate · % of participants
Induction
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 6 more results
10% (n=90) vs 11.5% (n=96) placebo @ 8wk160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
13.8% (n=87) vs 11.5% (n=96) placebo @ 8wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
13.8% (n=87) vs 11.5% (n=96) placebo @ 8wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
10% (n=130) vs 9.2% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
18.5% (n=130) vs 9.2% (n=130) placebo @ 8wk160/80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
16.5% (n=248) vs 9.3% (n=246) placebo @ 8wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
Clinical Response 50% (n=90) vs 35.4% (n=96) placebo @ 8wk160 mg/80 mg
responder rate · % of participants
Induction
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 4 more results
42.5% (n=87) vs 35.4% (n=96) placebo @ 8wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
54.6% (n=130) vs 44.6% (n=130) placebo @ 8wk160/80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
51.5% (n=130) vs 44.6% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
50.4% (n=248) vs 34.6% (n=246) placebo @ 8wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
Endoscopic Improvement 46.9% (n=130) vs 41.5% (n=130) placebo @ 8wk160/80/40
event count · % of participants
Induction
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 1 more result
37.7% (n=130) vs 41.5% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Rectal Bleeding Subscore 0 1 77.7% (n=130) vs 66.2% (n=130) placebo @ 8wk160/80/40
event count · % of participants
Induction
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 1 more result
70% (n=130) vs 66.2% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Physician Global Assessment Subscore 0 1 60% (n=130) vs 46.9% (n=130) placebo @ 8wk160/80/40
event count · % of participants
Induction
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 1 more result
53.8% (n=130) vs 46.9% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Stool Frequency Subscore 0 1 48.5% (n=130) vs 37.7% (n=130) placebo @ 8wk160/80/40
event count · % of participants
Induction
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 1 more result
36.2% (n=130) vs 37.7% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
IBDQ 42.2% (n=90) vs 39.6% (n=96) placebo @ 8wk160 mg/80 mg
responder rate · % of participants
Induction
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 4 more results
48.3% (n=87) vs 39.6% (n=96) placebo @ 8wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
60.8% (n=130) vs 57.7% (n=130) placebo @ 8wk160/80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
53.8% (n=130) vs 57.7% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
58.1% (n=248) vs 45.5% (n=246) placebo @ 8wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
Clinical Remission 20% (n=90) vs 7.3% (n=96) placebo @ 52wk160 mg/80 mg
responder rate · % of participants
Maintenance
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 14 more results
17.8% (n=90) vs 8.3% (n=96) placebo @ 32wk160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
20% (n=90) vs 7.3% (n=96) placebo @ 52wk160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
26.4% (n=87) vs 7.3% (n=96) placebo @ 52wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
17.2% (n=87) vs 8.3% (n=96) placebo @ 32wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
26.4% (n=87) vs 7.3% (n=96) placebo @ 52wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
17.3% (n=248) vs 8.5% (n=246) placebo @ 52wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
29% (n=31) vs 33.3% (n=12) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
45.2% (n=31) vs 33.3% (n=12) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
27.3% (n=33) vs 33.3% (n=12) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
42.9% (n=35) vs 33.3% (n=12) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
42.9% (n=21) vs 37.5% (n=8) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
45.5% (n=22) vs 37.5% (n=8) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
42.9% (n=21) vs 37.5% (n=8) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
44% (n=25) vs 37.5% (n=8) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
Sustained Clinical Remission 8.5% (n=248) vs 4.1% (n=246) placebo160/80/40
responder rate · % of participants
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
Clinical Response 37.8% (n=90) vs 20.8% (n=96) placebo @ 32wk160 mg/80 mg
responder rate · % of participants
Maintenance
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 8 more results
31.1% (n=90) vs 17.7% (n=96) placebo @ 52wk160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
33.3% (n=87) vs 20.8% (n=96) placebo @ 32wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
29.9% (n=87) vs 17.7% (n=96) placebo @ 52wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
30.2% (n=248) vs 18.3% (n=246) placebo @ 52wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
61.3% (n=31) vs 33.3% (n=12) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
67.7% (n=31) vs 33.3% (n=12) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
57.6% (n=33) vs 33.3% (n=12) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
65.7% (n=35) vs 33.3% (n=12) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
Sustained Clinical 23.8% (n=248) vs 12.2% (n=246) placebo160/80/40
responder rate · % of participants
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
Endoscopic Improvement 44.4% (n=90) vs 30.2% (n=96) placebo @ 8wk160 mg/80 mg
responder rate · % of participants
Induction
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 2 more results
39.1% (n=87) vs 30.2% (n=96) placebo @ 8wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
41.1% (n=248) vs 31.7% (n=246) placebo @ 8wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3

+ 51 further endpoints in the CSV export.

Psoriasis

Shared mechanism: TNF-alpha · full Psoriasis pipeline

adalimumab · Humira

Marketed by AbbVie and partners

Approved in Psoriasismonoclonal antibody (fully human IgG1)
Partial signal

NCT00195676 · Phase 3 · completed

Eligibility for this study required prior participation in an earlier adalimumab psoriasis trial, making this an open-label continuation rather than a fresh, independently controlled study. Within the retreatment group, 76.5% of patients regained clear or minimal skin at 16 weeks, but with no placebo or comparison arm in this phase, that rate cannot be attributed to the drug with the same confidence as a controlled trial.

Next expected readout: April 2028 · NCT07529925 (registry estimate)

Reported efficacy

Percentage of Participants With a Physician's Global Assessment of Clear or Minimal at Week 16 of Period R: PGA 0/1 at 16 weeks after adalimumab retreatment: 89% in patients without relapse vs 69% in patients who relapsed; median time to relapse 141 days (178/285 stable-control patients relapsed) (not_applicable)

Result source: NCT00195676

adalimumab-adbm (Cyltezo)

Marketed by Boehringer Ingelheim

Approved in Psoriasismonoclonal antibody
Weak signal

NCT03210259 · Phase 3 · completed

After a 14-week Humira run-in, 238 patients were randomized to switch between Cyltezo and Humira or continue Humira in a double-blind active-controlled period. Both primary pharmacokinetic comparisons met the prespecified equivalence range, but these were drug-level measures rather than direct clinical psoriasis outcomes, so the evidence is moderate. Its registered primary outcomes are pharmacokinetic measures with no comparison, so the evidence grade is capped at weak.

No aligned efficacy figure on record for this race.

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumabadalimumab-adbm (Cyltezo)
PASI 7577.8% vs 11.5%+66.3 vs placeboEow · wk 12 · n 338NCT01646073
7 other results
  • 80.1% vs 79% wk 16 · n 267 · Phase 3 · primary NCT02581345
  • 57.9% vs 32.4% 0.8 mg/kg · wk 16 · n 38 · Phase 3 · primary NCT01251614
  • 43.6% vs 32.4% 0.4 mg/kg · wk 16 · n 39 · Phase 3 · primary NCT01251614
  • 45.3% vs 2.3% Eow · wk 7 · n 338 · Phase 3 · secondary NCT01646073
  • 9.8% vs 0% Eow · wk 3 · n 338 · Phase 3 · secondary NCT01646073
  • 30.6% vs 8.7% wk 16 · n 49 · Phase 4 · secondary NCT00735787
  • 67% vs 27% wk 16 · n 15 · Phase 4 · secondary NCT00932113
—Not reported
PASI 9061.8% vs 54.2%vs EU RPPwk 16 · n 267NCT02581345
3 other results
  • 28.9% vs 21.6% 0.8 mg/kg · wk 16 · n 38 · Phase 3 · secondary NCT01251614
  • 30.8% vs 21.6% 0.4 mg/kg · wk 16 · n 39 · Phase 3 · secondary NCT01251614
  • 20.4% vs 0% wk 16 · n 49 · Phase 4 · secondary NCT00735787
—Not reported
PASI 10018.4% vs 2.7%vs Methotrexate0.8 mg/kg · wk 16 · n 38NCT01251614
2 other results
  • 10.3% vs 2.7% 0.4 mg/kg · wk 16 · n 39 · Phase 3 · secondary NCT01251614
  • 14.3% vs 0% wk 16 · n 49 · Phase 4 · secondary NCT00735787
—Not reported
sPGA 0/160.5% vs 40.5%vs Methotrexate0.8 mg/kg · wk 16 · n 38NCT01251614
11 other results
  • 41% vs 40.5% 0.4 mg/kg · wk 16 · n 39 · Phase 3 · primary NCT01251614
  • 80.5% vs 14.9% Eow · wk 12 · n 338 · Phase 3 · secondary NCT01646073
  • 57.4% vs 4.6% Eow · wk 7 · n 338 · Phase 3 · secondary NCT01646073
  • 20.1% vs 0% Eow · wk 3 · n 338 · Phase 3 · secondary NCT01646073
  • 68.9% vs 66.1% wk 16 · n 267 · Phase 3 · secondary NCT02581345
  • 30.6% vs 4.3% wk 16 · n 49 · Phase 4 · primary NCT00735787
  • 28.6% vs 13% wk 12 · n 49 · Phase 4 · secondary NCT00735787
  • 24.5% vs 8.7% wk 8 · n 49 · Phase 4 · secondary NCT00735787
  • 20.4% vs 4.3% wk 4 · n 49 · Phase 4 · secondary NCT00735787
  • 8.2% vs 4.3% wk 2 · n 49 · Phase 4 · secondary NCT00735787
  • 73% vs 27% wk 16 · n 15 · Phase 4 · secondary NCT00932113
—Not reported
DLQI, change-4.8 vs -4.2−0.6 vs placebowk 16 · n 49NCT00735787
3 other results
  • -7.9 vs -3.7 wk 12 · n 33 · Phase 4 · secondary NCT01553058
  • -4.1 vs -3.1 wk 8 · n 49 · Phase 4 · secondary NCT00735787
  • -4.3 vs -3.4 wk 2 · n 49 · Phase 4 · secondary NCT00735787
—Not reported

PASI 75

adalimumab
77.8% vs 11.5%+66.3 vs placeboEow · wk 12 · n 338NCT01646073
7 other results
  • 80.1% vs 79% wk 16 · n 267 · Phase 3 · primary NCT02581345
  • 57.9% vs 32.4% 0.8 mg/kg · wk 16 · n 38 · Phase 3 · primary NCT01251614
  • 43.6% vs 32.4% 0.4 mg/kg · wk 16 · n 39 · Phase 3 · primary NCT01251614
  • 45.3% vs 2.3% Eow · wk 7 · n 338 · Phase 3 · secondary NCT01646073
  • 9.8% vs 0% Eow · wk 3 · n 338 · Phase 3 · secondary NCT01646073
  • 30.6% vs 8.7% wk 16 · n 49 · Phase 4 · secondary NCT00735787
  • 67% vs 27% wk 16 · n 15 · Phase 4 · secondary NCT00932113
adalimumab-adbm (Cyltezo)
—Not reported

PASI 90

adalimumab
61.8% vs 54.2%vs EU RPPwk 16 · n 267NCT02581345
3 other results
  • 28.9% vs 21.6% 0.8 mg/kg · wk 16 · n 38 · Phase 3 · secondary NCT01251614
  • 30.8% vs 21.6% 0.4 mg/kg · wk 16 · n 39 · Phase 3 · secondary NCT01251614
  • 20.4% vs 0% wk 16 · n 49 · Phase 4 · secondary NCT00735787
adalimumab-adbm (Cyltezo)
—Not reported

PASI 100

adalimumab
18.4% vs 2.7%vs Methotrexate0.8 mg/kg · wk 16 · n 38NCT01251614
2 other results
  • 10.3% vs 2.7% 0.4 mg/kg · wk 16 · n 39 · Phase 3 · secondary NCT01251614
  • 14.3% vs 0% wk 16 · n 49 · Phase 4 · secondary NCT00735787
adalimumab-adbm (Cyltezo)
—Not reported

sPGA 0/1

adalimumab
60.5% vs 40.5%vs Methotrexate0.8 mg/kg · wk 16 · n 38NCT01251614
11 other results
  • 41% vs 40.5% 0.4 mg/kg · wk 16 · n 39 · Phase 3 · primary NCT01251614
  • 80.5% vs 14.9% Eow · wk 12 · n 338 · Phase 3 · secondary NCT01646073
  • 57.4% vs 4.6% Eow · wk 7 · n 338 · Phase 3 · secondary NCT01646073
  • 20.1% vs 0% Eow · wk 3 · n 338 · Phase 3 · secondary NCT01646073
  • 68.9% vs 66.1% wk 16 · n 267 · Phase 3 · secondary NCT02581345
  • 30.6% vs 4.3% wk 16 · n 49 · Phase 4 · primary NCT00735787
  • 28.6% vs 13% wk 12 · n 49 · Phase 4 · secondary NCT00735787
  • 24.5% vs 8.7% wk 8 · n 49 · Phase 4 · secondary NCT00735787
  • 20.4% vs 4.3% wk 4 · n 49 · Phase 4 · secondary NCT00735787
  • 8.2% vs 4.3% wk 2 · n 49 · Phase 4 · secondary NCT00735787
  • 73% vs 27% wk 16 · n 15 · Phase 4 · secondary NCT00932113
adalimumab-adbm (Cyltezo)
—Not reported

DLQI, change

adalimumab
-4.8 vs -4.2−0.6 vs placebowk 16 · n 49NCT00735787
3 other results
  • -7.9 vs -3.7 wk 12 · n 33 · Phase 4 · secondary NCT01553058
  • -4.1 vs -3.1 wk 8 · n 49 · Phase 4 · secondary NCT00735787
  • -4.3 vs -3.4 wk 2 · n 49 · Phase 4 · secondary NCT00735787
adalimumab-adbm (Cyltezo)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

adalimumab-adbm (Cyltezo): registry results are on file for Psoriasis, but their comparison mappings are not yet available.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. adalimumab: 4 of 4 rows · adalimumab-adbm (Cyltezo): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumab
Dropout rate
41.3%a
NCT00195676 · Phase 3
show 35 more results
6.7%
NCT00932113 · Phase 4 · registry result, not featured evidence
3%
NCT01553058 · Phase 4 · registry result, not featured evidence
0%
NCT01644396 · Phase 4 · registry result, not featured evidence
4.7%
NCT01265823 · Phase 4 · registry result, not featured evidence
16.3%
NCT00735787 · Phase 4 · registry result, not featured evidence
9.4%
NCT05637515 · Phase 3 · registry result, not featured evidence
50%
NCT02533375 · Phase 3 · registry result, not featured evidence
5.2%Part 1 and Part 2: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
—Part 1: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
—Part 2: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
13.8%EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
—EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
—EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
21.1%0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
33.3%0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
1.5%Eow
NCT01646073 · Phase 3 · registry result, not featured evidence
—Eow
NCT01646073 · Phase 3 · registry result, not featured evidence
11%Sub-optimal Response to Etanercept
NCT00566722 · Phase 3 · registry result, not featured evidence
4.9%Sub-optimal Response to MTX
NCT00566722 · Phase 3 · registry result, not featured evidence
17.2%Sub-optimal Response to Narrow-ban
NCT00566722 · Phase 3 · registry result, not featured evidence
—40 mg every week
NCT00927069 · Phase 3 · registry result, not featured evidence
—40 mg every week
NCT00927069 · Phase 3 · registry result, not featured evidence
2%Group A
NCT00927069 · Phase 3 · registry result, not featured evidence
2.9%Group B
NCT00927069 · Phase 3 · registry result, not featured evidence
7.7%Adalimumab + Calcipotriol/Betameth
NCT00574249 · Phase 3 · registry result, not featured evidence · combination
7.1%Adalimumab + Placebo
NCT00574249 · Phase 3 · registry result, not featured evidence
11.8%40 mg Eow
NCT00513370 · Phase 3 · registry result, not featured evidence
22.4%80 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence
24.7%40 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence
0%
NCT01872546 · Phase 2 · registry result, not featured evidence
11.1%
NCT01320293 · Phase na · registry result, not featured evidence
Discontinued due to AEs
5.6%a
NCT00195676 · Phase 3
show 35 more results
—
NCT00932113 · Phase 4 · registry result, not featured evidence
—
NCT01553058 · Phase 4 · registry result, not featured evidence
—
NCT01644396 · Phase 4 · registry result, not featured evidence
—
NCT01265823 · Phase 4 · registry result, not featured evidence
—
NCT00735787 · Phase 4 · registry result, not featured evidence
—
NCT05637515 · Phase 3 · registry result, not featured evidence
20%
NCT02533375 · Phase 3 · registry result, not featured evidence
1%Part 1 and Part 2: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
—Part 1: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
—Part 2: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
4.6%EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
—EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
—EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
2.6%0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
0%0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
0.6%Eow
NCT01646073 · Phase 3 · registry result, not featured evidence
—Eow
NCT01646073 · Phase 3 · registry result, not featured evidence
0%Sub-optimal Response to Etanercept
NCT00566722 · Phase 3 · registry result, not featured evidence
0%Sub-optimal Response to MTX
NCT00566722 · Phase 3 · registry result, not featured evidence
6.9%Sub-optimal Response to Narrow-ban
NCT00566722 · Phase 3 · registry result, not featured evidence
—40 mg every week
NCT00927069 · Phase 3 · registry result, not featured evidence
—40 mg every week
NCT00927069 · Phase 3 · registry result, not featured evidence
—Group A
NCT00927069 · Phase 3 · registry result, not featured evidence
—Group B
NCT00927069 · Phase 3 · registry result, not featured evidence
4.9%Adalimumab + Calcipotriol/Betameth
NCT00574249 · Phase 3 · registry result, not featured evidence · combination
1.6%Adalimumab + Placebo
NCT00574249 · Phase 3 · registry result, not featured evidence
—40 mg Eow
NCT00513370 · Phase 3 · registry result, not featured evidence
—80 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence
—40 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence
—
NCT01872546 · Phase 2 · registry result, not featured evidence
5.6%
NCT01320293 · Phase na · registry result, not featured evidence
Serious AEs
12.9%a
NCT00195676 · Phase 3
show 35 more results
0%
NCT00932113 · Phase 4 · registry result, not featured evidence
6.1%
NCT01553058 · Phase 4 · registry result, not featured evidence
0%
NCT01644396 · Phase 4 · registry result, not featured evidence
0.7%
NCT01265823 · Phase 4 · registry result, not featured evidence
4.1%
NCT00735787 · Phase 4 · registry result, not featured evidence
1.7%
NCT05637515 · Phase 3 · registry result, not featured evidence
30%
NCT02533375 · Phase 3 · registry result, not featured evidence
—Part 1 and Part 2: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
1.4%Part 1: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
3.7%Part 2: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
—EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
7.3%EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
3.2%EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
0%0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
0%0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
5.7%0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
7.7%0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
0%0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
0%0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—Eow
NCT01646073 · Phase 3 · registry result, not featured evidence
1.2%Eow
NCT01646073 · Phase 3 · registry result, not featured evidence
4.9%Sub-optimal Response to Etanercept
NCT00566722 · Phase 3 · registry result, not featured evidence
0%Sub-optimal Response to MTX
NCT00566722 · Phase 3 · registry result, not featured evidence
3.4%Sub-optimal Response to Narrow-ban
NCT00566722 · Phase 3 · registry result, not featured evidence
—40 mg every week
NCT00927069 · Phase 3 · registry result, not featured evidence
—40 mg every week
NCT00927069 · Phase 3 · registry result, not featured evidence
0%Group A
NCT00927069 · Phase 3 · registry result, not featured evidence
0%Group B
NCT00927069 · Phase 3 · registry result, not featured evidence
4.4%Adalimumab + Calcipotriol/Betameth
NCT00574249 · Phase 3 · registry result, not featured evidence · combination
4.1%Adalimumab + Placebo
NCT00574249 · Phase 3 · registry result, not featured evidence
—40 mg Eow
NCT00513370 · Phase 3 · registry result, not featured evidence
19%80 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence
21.3%40 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence
0%
NCT01872546 · Phase 2 · registry result, not featured evidence
5.6%
NCT01320293 · Phase na · registry result, not featured evidence
Most frequent reported AEs
a
nasopharyngitis 26.6%
upper respiratory tract infection 20.3%
headache 11.2%
NCT00195676 · Phase 3
show 29 more results
upper respiratory tract infection 40%
dizziness 13.3%
flu-like symptoms 13.3%
NCT00932113 · Phase 4 · registry result, not featured evidence
upper respiratory infection 9.1% (placebo 12.9%)
joint range of motion decrease 6.1% (placebo 0%)
headache 3% (placebo 6.5%)
NCT01553058 · Phase 4 · registry result, not featured evidence
latent tuberculosis 8%
rhinitis 6%
alanine aminotransferase increased 2%
NCT01644396 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 11.3%
hyperglycemia 10.7%
arthralgia 6.7%
NCT01265823 · Phase 4 · registry result, not featured evidence
nasopharyngitis 26.5% (placebo 13%)
headache 14.3% (placebo 4.3%)
cough 8.2% (placebo 4.3%)
NCT00735787 · Phase 4 · registry result, not featured evidence
headache 2.2%
nasopharyngitis 2.2%
upper respiratory tract infection 2.2%
NCT05637515 · Phase 3 · registry result, not featured evidence
nasopharyngitis 30%
pruritus 30%
hypoalbuminaemia 20%
NCT02533375 · Phase 3 · registry result, not featured evidence
injection site reaction 23.9%
nasopharyngitis 6.7%
headache 3.2%
NCT02581345 · Phase 3 · registry result, not featured evidence
nasopharyngitis 14.8%
psoriasis 10.3%
injection site reaction 10%
NCT02581345 · Phase 3 · registry result, not featured evidence
EOW
upper respiratory tract infection 8.3% (placebo 8.3%)
headache 5.5% (placebo 0%)
nasopharyngitis 5.5% (placebo 9.3%)
NCT02016482 · Phase 3 · registry result, not featured evidence
EOW
nasopharyngitis 12.8% (placebo 9.3%)
upper respiratory tract infection 4.3% (placebo 8.3%)
depression 3.2% (placebo 0.9%)
NCT02016482 · Phase 3 · registry result, not featured evidence
0.8 mg/kg
nasopharyngitis 21.1%
headache 15.8%
dry skin 7.9%
NCT01251614 · Phase 3 · registry result, not featured evidence
0.8 mg/kg
nasopharyngitis 18.5%
back pain 11.1%
headache 11.1%
NCT01251614 · Phase 3 · registry result, not featured evidence
0.8 mg/kg
nasopharyngitis 28.7%
headache 25.3%
upper respiratory tract infection 14.9%
NCT01251614 · Phase 3 · registry result, not featured evidence
0.4 mg/kg
nasopharyngitis 25.6%
headache 17.9%
cough 10.3%
NCT01251614 · Phase 3 · registry result, not featured evidence
0.4 mg/kg
cough 18.2%
decreased appetite 9.1%
gastroenteritis 9.1%
NCT01251614 · Phase 3 · registry result, not featured evidence
0.4 mg/kg
nasopharyngitis 23.1%
agitation 7.7%
cough 7.7%
NCT01251614 · Phase 3 · registry result, not featured evidence
Eow
upper respiratory tract infection 10.1% (placebo 6.9%)
oropharyngeal pain 4.1% (placebo 1.1%)
nasopharyngitis 3.8% (placebo 5.7%)
NCT01646073 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 6.1%
cough 3.7%
headache 3.7%
NCT00566722 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 12.2%
injection site erythema 7.3%
nasopharyngitis 7.3%
NCT00566722 · Phase 3 · registry result, not featured evidence
fatigue 6.9%
pharyngitis 6.9%
abdominal pain 3.4%
NCT00566722 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 18%
back pain 8%
common cold 8%
NCT00927069 · Phase 3 · registry result, not featured evidence
headache 11.4%
common cold 5.7%
upper respiratory tract infection 5.7%
NCT00927069 · Phase 3 · registry result, not featured evidence
nasopharyngitis 8.7%
headache 5.2%
psoriasis 5.2%
NCT00574249 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 6.3%
headache 6%
pruritus 5.8%
NCT00574249 · Phase 3 · registry result, not featured evidence
40 mg Eow
nasopharyngitis 10.8%
upper respiratory tract infection 10.8%
headache 4.9%
NCT00513370 · Phase 3 · registry result, not featured evidence
80 mg every other week
nasopharyngitis 77.6%
blood triglycerides increased 29.3%
blood creatine phosphokinase increased 25.9%
NCT00647400 · Phase 2/3 · registry result, not featured evidence
40 mg every other week
nasopharyngitis 75.3%
blood triglycerides increased 24.7%
alanine aminotransferase increased 23.6%
NCT00647400 · Phase 2/3 · registry result, not featured evidence
upper respiratory tract infection 22.2%
elbow strain 5.6%
heartburn 5.6%
NCT01320293 · Phase na · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab

sPGA 0/1 30.4% (n=23) @ 24wk40 mg every week
responder rate · % of participants
No placebo or comparator arm
NCT00927069 · Phase 3 · registry result, not featured evidence · converted to % from 7 Participants as posted
show 27 more results
32.3% (n=31) @ 24wk*40 mg every week
NCT00927069 · Phase 3 · registry result, not featured evidence · converted to % from 10 Participants as posted
50.6% (n=1256) @ 60wk
NCT00195676 · Phase 3
46.3% (n=1256) @ 120wk
NCT00195676 · Phase 3
2% (n=50) @ 2wk
NCT01644396 · Phase 4 · registry result, not featured evidence
12% (n=50) @ 4wk
NCT01644396 · Phase 4 · registry result, not featured evidence
34% (n=50) @ 8wk
NCT01644396 · Phase 4 · registry result, not featured evidence
72% (n=50) @ 12wk
NCT01644396 · Phase 4 · registry result, not featured evidence
86% (n=50) @ 16wk
NCT01644396 · Phase 4 · registry result, not featured evidence
80% (n=50) @ 24wk
NCT01644396 · Phase 4 · registry result, not featured evidence
85.6% (n=333) @ 16wkEow
NCT01646073 · Phase 3 · registry result, not featured evidence
84.4% (n=333) @ 19wkEow
NCT01646073 · Phase 3 · registry result, not featured evidence
83.8% (n=333) @ 24wkEow
NCT01646073 · Phase 3 · registry result, not featured evidence
61% (n=41) @ 16wk*
NCT00566722 · Phase 3 · registry result, not featured evidence · converted to % from 25 Participants as posted
48.3% (n=29) @ 16wk*
NCT00566722 · Phase 3 · registry result, not featured evidence · converted to % from 14 Participants as posted
48.8% (n=82) @ 16wk*
NCT00566722 · Phase 3 · registry result, not featured evidence · converted to % from 40 Participants as posted
31.4% (n=35) @ 12wk*
NCT00927069 · Phase 3 · registry result, not featured evidence · converted to % from 11 Participants as posted
34% (n=50) @ 12wk*
NCT00927069 · Phase 3 · registry result, not featured evidence · converted to % from 17 Participants as posted
7.1% (n=364) @ 2wk
NCT00574249 · Phase 3 · registry result, not featured evidence
13.9% (n=366) @ 2wk
NCT00574249 · Phase 3 · registry result, not featured evidence · combination
24.5% (n=364) @ 4wk
NCT00574249 · Phase 3 · registry result, not featured evidence
33.1% (n=366) @ 4wk
NCT00574249 · Phase 3 · registry result, not featured evidence · combination
46.2% (n=364) @ 8wk
NCT00574249 · Phase 3 · registry result, not featured evidence
42.9% (n=366) @ 8wk
NCT00574249 · Phase 3 · registry result, not featured evidence · combination
64.8% (n=364) @ 12wk
NCT00574249 · Phase 3 · registry result, not featured evidence
50% (n=366) @ 12wk
NCT00574249 · Phase 3 · registry result, not featured evidence · combination
64.6% (n=364) @ 16wk
NCT00574249 · Phase 3 · registry result, not featured evidence
56.6% (n=366) @ 16wk
NCT00574249 · Phase 3 · registry result, not featured evidence · combination
PASI 75 77.6% (n=58) @ 12wk80 mg every other week
responder rate · % of participants
No placebo or comparator arm
NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 45 Participants as posted
show 39 more results
86.2% (n=58) @ 24wk*80 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 50 Participants as posted
87.9% (n=58) @ 36wk*80 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 51 Participants as posted
82.8% (n=58) @ 52wk*80 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 48 Participants as posted
81% (n=58) @ 76wk*80 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 47 Participants as posted
74.1% (n=58) @ 100wk*80 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 43 Participants as posted
70.7% (n=58) @ 160wk*80 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 41 Participants as posted
22.4% (n=58) @ 208wk*80 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 13 Participants as posted
75.4% (n=191) @ 16wk*40 mg Eow
Responder
NCT00513370 · Phase 3 · registry result, not featured evidence · converted to % from 144 participants as posted
60.7% (n=89) @ 12wk*40 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 54 Participants as posted
77.5% (n=89) @ 24wk*40 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 69 Participants as posted
73% (n=89) @ 36wk*40 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 65 Participants as posted
75.3% (n=89) @ 52wk*40 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 67 Participants as posted
78.7% (n=89) @ 76wk*40 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 70 Participants as posted
74.2% (n=89) @ 100wk*40 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 66 Participants as posted
77.5% (n=89) @ 160wk*40 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 69 Participants as posted
30.3% (n=89) @ 208wk*40 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 27 Participants as posted
61.4% (n=1256) @ 60wk
NCT00195676 · Phase 3
57.3% (n=1256) @ 120wk
NCT00195676 · Phase 3
82% (n=50) @ 24wk
NCT01644396 · Phase 4 · registry result, not featured evidence
0% (n=50) @ 2wk
NCT01644396 · Phase 4 · registry result, not featured evidence
4% (n=50) @ 4wk
NCT01644396 · Phase 4 · registry result, not featured evidence
44% (n=50) @ 8wk
NCT01644396 · Phase 4 · registry result, not featured evidence
76% (n=50) @ 12wk
NCT01644396 · Phase 4 · registry result, not featured evidence
82% (n=50) @ 16wk
NCT01644396 · Phase 4 · registry result, not featured evidence
31% (n=150) @ 4wk
NCT01265823 · Phase 4 · registry result, not featured evidence
85% (n=150) @ 16wk
NCT01265823 · Phase 4 · registry result, not featured evidence
20% (n=10) @ 2wk*
NCT02533375 · Phase 3 · registry result, not featured evidence · converted to % from 2 Participants as posted
20% (n=10) @ 4wk*
NCT02533375 · Phase 3 · registry result, not featured evidence · converted to % from 2 Participants as posted
20% (n=10) @ 8wk*
NCT02533375 · Phase 3 · registry result, not featured evidence · converted to % from 2 Participants as posted
20% (n=10) @ 12wk*
NCT02533375 · Phase 3 · registry result, not featured evidence · converted to % from 2 Participants as posted
40% (n=10) @ 16wk*
NCT02533375 · Phase 3 · registry result, not featured evidence · converted to % from 4 Participants as posted
40% (n=10) @ 24wk*
NCT02533375 · Phase 3 · registry result, not featured evidence · converted to % from 4 Participants as posted
50% (n=10) @ 36wk*
NCT02533375 · Phase 3 · registry result, not featured evidence · converted to % from 5 Participants as posted
30% (n=10) @ 52wk*
NCT02533375 · Phase 3 · registry result, not featured evidence · converted to % from 3 Participants as posted
87.4% (n=333) @ 16wkEow
NCT01646073 · Phase 3 · registry result, not featured evidence
87.1% (n=333) @ 19wkEow
NCT01646073 · Phase 3 · registry result, not featured evidence
87.7% (n=333) @ 24wkEow
NCT01646073 · Phase 3 · registry result, not featured evidence
70.9% (n=364) @ 16wk
NCT00574249 · Phase 3 · registry result, not featured evidence
64.8% (n=366) @ 16wk
NCT00574249 · Phase 3 · registry result, not featured evidence · combination
PASI 75 57.9% (n=38) vs 32.4% (n=37) Methotrexate @ 16wk0.8 mg/kg
responder rate · % of participants
NCT01251614 · Phase 3 · registry result, not featured evidence
show 9 more results
43.6% (n=39) vs 32.4% (n=37) Methotrexate @ 16wk0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
67% (n=15) vs 27% (n=15) Methotrexate (MTX) @ 16wk
NCT00932113 · Phase 4 · registry result, not featured evidence
30.6% (n=49) vs 8.7% (n=23) placebo @ 16wk*
NCT00735787 · Phase 4 · registry result, not featured evidence · converted to % from 15 subjects as posted
22.4% (n=49) vs 17.4% (n=23) placebo @ 28wk*
NCT00735787 · Phase 4 · registry result, not featured evidence · converted to % from 11 subjects as posted
80.1% (n=267) vs 79% (n=271) EU RPP @ 16wk
NCT02581345 · Phase 3 · registry result, not featured evidence
78.3% (n=258) vs 73.8% (n=130) EU RPP @ 52wk*
NCT02581345 · Phase 3 · registry result, not featured evidence · converted to % from 202 Participants as posted
77.8% (n=338) vs 11.5% (n=87) placebo @ 12wkEow
NCT01646073 · Phase 3 · registry result, not featured evidence
9.8% (n=338) vs 0% (n=87) placebo @ 3wkEow
NCT01646073 · Phase 3 · registry result, not featured evidence
45.3% (n=338) vs 2.3% (n=87) placebo @ 7wkEow
NCT01646073 · Phase 3 · registry result, not featured evidence
sPGA 0/1 60.5% (n=38) vs 40.5% (n=37) Methotrexate @ 16wk0.8 mg/kg
responder rate · % of participants
NCT01251614 · Phase 3 · registry result, not featured evidence
show 16 more results
52.6% (n=19) vs 62.5% (n=8) Methotrexate0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
41% (n=39) vs 40.5% (n=37) Methotrexate @ 16wk0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
27.3% (n=11) vs 62.5% (n=8) Methotrexate0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
73% (n=15) vs 27% (n=15) Methotrexate (MTX) @ 16wk
NCT00932113 · Phase 4 · registry result, not featured evidence
30.6% (n=49) vs 4.3% (n=23) placebo @ 16wk*
NCT00735787 · Phase 4 · registry result, not featured evidence · converted to % from 15 subjects as posted
8.2% (n=49) vs 4.3% (n=23) placebo @ 2wk*
NCT00735787 · Phase 4 · registry result, not featured evidence · converted to % from 4 subjects as posted
20.4% (n=49) vs 4.3% (n=23) placebo @ 4wk*
NCT00735787 · Phase 4 · registry result, not featured evidence · converted to % from 10 subjects as posted
24.5% (n=49) vs 8.7% (n=23) placebo @ 8wk*
NCT00735787 · Phase 4 · registry result, not featured evidence · converted to % from 12 subjects as posted
28.6% (n=49) vs 13% (n=23) placebo @ 12wk*
NCT00735787 · Phase 4 · registry result, not featured evidence · converted to % from 14 subjects as posted
22.4% (n=49) vs 21.7% (n=23) placebo @ 20wk*
NCT00735787 · Phase 4 · registry result, not featured evidence · converted to % from 11 subjects as posted
24.5% (n=49) vs 21.7% (n=23) placebo @ 24wk*
NCT00735787 · Phase 4 · registry result, not featured evidence · converted to % from 12 subjects as posted
24.5% (n=49) vs 8.7% (n=23) placebo @ 28wk*
NCT00735787 · Phase 4 · registry result, not featured evidence · converted to % from 12 subjects as posted
68.9% (n=267) vs 66.1% (n=271) EU RPP @ 16wk
NCT02581345 · Phase 3 · registry result, not featured evidence
20.1% (n=338) vs 0% (n=87) placebo @ 3wkEow
NCT01646073 · Phase 3 · registry result, not featured evidence
57.4% (n=338) vs 4.6% (n=87) placebo @ 7wkEow
NCT01646073 · Phase 3 · registry result, not featured evidence
80.5% (n=338) vs 14.9% (n=87) placebo @ 12wkEow
NCT01646073 · Phase 3 · registry result, not featured evidence
BSA Involvement 5.9% (n=15) vs 10.7% (n=15) Methotrexate (MTX) @ 16wk
absolute value · percentage points
NCT00932113 · Phase 4 · registry result, not featured evidence
Target Lesion TOTAL 1.2 vs 3.4 Methotrexate (MTX) score @ 16wk
absolute change · score
NCT00932113 · Phase 4 · registry result, not featured evidence
Aortic Vascular Inflammation TBR -0.067 vs -0.052 placebo ratio @ 12wk
absolute change · ratio
NCT01553058 · Phase 4 · registry result, not featured evidence
Total Cholesterol Change mg/dL 1.48 vs 5 placebo mg/dL @ 12wk
absolute change · mg/dL
NCT01553058 · Phase 4 · registry result, not featured evidence
PASI 75 46.9% (n=32) vs 6.7% (n=30) placebo @ 12wk
responder rate · % of participants
PASI75
NCT01553058 · Phase 4 · registry result, not featured evidence · converted to % from 15 Participants as posted
PGA 0-1 43.8% (n=32) vs 6.7% (n=30) placebo @ 12wk
responder rate · % of participants
PGA Clear/Almost Clear
NCT01553058 · Phase 4 · registry result, not featured evidence · converted to % from 14 Participants as posted
EQ-5D 0.07 vs 0 placebo score @ 12wk
absolute change · score
NCT01553058 · Phase 4 · registry result, not featured evidence
DLQI -7.91 vs -3.73 placebo score @ 12wk
absolute change · score
NCT01553058 · Phase 4 · registry result, not featured evidence
show 5 more results
-4.35 vs -3.43 placebo score @ 2wk
NCT00735787 · Phase 4 · registry result, not featured evidence
-4.08 vs -3.09 placebo score @ 8wk
NCT00735787 · Phase 4 · registry result, not featured evidence
-4.78 vs -4.22 placebo score @ 16wk
NCT00735787 · Phase 4 · registry result, not featured evidence
-5.18 vs -4.74 placebo score @ 28wk
NCT00735787 · Phase 4 · registry result, not featured evidence
-8 vs -1.9 placebo score @ 26wkEOW
NCT02016482 · Phase 3 · registry result, not featured evidence

+ 181 further endpoints in the CSV export.

Rheumatoid Arthritis

Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline

adalimumab · Humira

Marketed by AbbVie and partners

Approved in Rheumatoid Arthritismonoclonal antibody (fully human IgG1)
Reliable signal

NCT00195702 · Phase 3 · completed

This was a large, randomized, double-blind, placebo-controlled trial. More patients on adalimumab responded on the ACR20 joint-response measure than on placebo (about 61-63% vs about 30%, p<0.001 for both doses), and adalimumab also significantly slowed radiographic joint damage and improved physical function compared with placebo (p<0.001 for both).

Next expected readout: December 2027 · NCT06440629 (registry estimate)

Reported efficacy

Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 24; Change From Baseline in Modified Total Sharp X-ray Score at Week 52 (Baseline and Week 52); Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 52 (Baseline and Week 52): Primary 1, ACR20 at week 24: 63% (40 mg every other week) and 61% (20 mg weekly) vs 30% placebo, all with methotrexate (P<=0.001 for each), met. Primary 2, change in modified total Sharp score at week 52: 0.1 and 0.8 vs 2.7 (P<=0.001 for each), met. Primary 3, change in HAQ disability index at week 52: -0.59 and -0.61 vs -0.25 (P<=0.001 for each), met. (met)

Result source: NCT00195702

adalimumab-adbm (Cyltezo)

Marketed by Boehringer Ingelheim

Approved in Rheumatoid Arthritismonoclonal antibody
Reliable signal

NCT02137226 · Phase 3 · completed

The 645-participant study was randomized, double-blind, and active-controlled against US-licensed Humira, with ACR20 response as the primary clinical endpoint. The prespecified equivalence margins were met at both Week 12 and Week 24, so the comparison supports equivalent clinical response between BI 695501 and Humira.

No aligned efficacy figure on record for this race.

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumabadalimumab-adbm (Cyltezo)
ACR2063.3% vs 29.5%+33.8 vs placebo40 mg every other week · wk 24 · n 207NCT00195702
28 other results
  • 50.3% vs 33.9% 40 mg every other week · wk 12 · n 159 · Phase 3 · primary NCT00647270
  • 57% vs 35% 40 mg · wk 12 · n 121 · Phase 2/3 · primary NCT00538902
  • 47.3% vs 33.9% 80 mg monthly · wk 12 · n 205 · Phase 3 · primary NCT00647270
  • 51.2% vs 35% 80 mg · wk 12 · n 121 · Phase 2/3 · primary NCT00538902
  • 60.8% vs 29.5% 20 mg weekly · wk 24 · n 212 · Phase 3 · primary NCT00195702
  • 58.9% vs 24% 40 mg every other week · wk 52 · n 207 · Phase 3 · secondary NCT00195702
  • 54.7% vs 24% 20 mg weekly · wk 52 · n 212 · Phase 3 · secondary NCT00195702
  • 75.4% vs 56.4% wk 26 · n 171 · Phase 3 · secondary NCT00870467
  • 49.3% vs 56% wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 69.4% vs 56% wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 50% vs 59.9% wk 76 · n 274 · Phase 3 · secondary NCT00195663
  • 69% vs 59.9% wk 76 · n 268 · Phase 3 · secondary NCT00195663
  • 54.4% vs 62.6% wk 52 · n 274 · Phase 3 · secondary NCT00195663
  • 72.8% vs 62.6% wk 52 · n 268 · Phase 3 · secondary NCT00195663
  • 53.3% vs 61.5% wk 26 · n 274 · Phase 3 · secondary NCT00195663
  • 68.7% vs 61.5% wk 26 · n 268 · Phase 3 · secondary NCT00195663
  • 69.2% vs 71.4% wk 12 · n 454 · Phase 4 · primary NCT01500278
  • 84.8% vs 80.4% wk 78 · n 105 · Phase 4 · secondary NCT00420927
  • 66.4% vs 80.4% wk 78 · n 259 · Phase 4 · secondary NCT00420927
  • 64.5% vs 60.8% wk 6 · n 454 · Phase 4 · secondary NCT01500278
  • 68% vs 68% 40 mg every other week · wk 24 · n 50 · Phase 2 · secondary NCT01712178
  • 62% vs 68% 40 mg every other week · wk 12 · n 50 · Phase 2 · secondary NCT01712178
  • 46.2% vs 65.7% wk 104 · n 39 · Phase 4 · secondary NCT01162421
  • 51.3% vs 65.7% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 56.4% vs 68.6% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 66.7% vs 60% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 64.1% vs 37.1% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 69.2% vs 57.1% wk 13 · n 39 · Phase 4 · secondary NCT01162421
—Not reported
ACR5041.2% vs 45.9%vs Methotrexatewk 52 · n 274NCT00195663
19 other results
  • 61.6% vs 45.9% wk 52 · n 268 · Phase 3 · primary NCT00195663
  • 64.3% vs 38.7% wk 26 · n 171 · Phase 3 · secondary NCT00870467
  • 36.9% vs 42.8% wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 59% vs 42.8% wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 41.6% vs 44.4% wk 76 · n 274 · Phase 3 · secondary NCT00195663
  • 60.1% vs 44.4% wk 76 · n 268 · Phase 3 · secondary NCT00195663
  • 35% vs 40.5% wk 26 · n 274 · Phase 3 · secondary NCT00195663
  • 58.6% vs 40.5% wk 26 · n 268 · Phase 3 · secondary NCT00195663
  • 78.1% vs 69.6% wk 78 · n 105 · Phase 4 · secondary NCT00420927
  • 46.3% vs 69.6% wk 78 · n 259 · Phase 4 · secondary NCT00420927
  • 48% vs 50% 40 mg every other week · wk 24 · n 50 · Phase 2 · secondary NCT01712178
  • 36% vs 40% 40 mg every other week · wk 12 · n 50 · Phase 2 · secondary NCT01712178
  • 33.3% vs 42.9% wk 104 · n 39 · Phase 4 · secondary NCT01162421
  • 38.5% vs 45.7% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 43.6% vs 34.3% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 48.7% vs 40% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 43.6% vs 22.9% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 38.5% vs 22.9% wk 13 · n 39 · Phase 4 · secondary NCT01162421
  • 64.7% vs 51.6% wk 12 · n 17 · Phase 2 · secondary NCT03823391
—Not reported
ACR7047.4% vs 22.7%+24.7 vs placebowk 26 · n 171NCT00870467
16 other results
  • 28.1% vs 28.4% wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 46.6% vs 28.4% wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 28.8% vs 29.2% wk 76 · n 274 · Phase 3 · secondary NCT00195663
  • 47.4% vs 29.2% wk 76 · n 268 · Phase 3 · secondary NCT00195663
  • 25.9% vs 27.2% wk 52 · n 274 · Phase 3 · secondary NCT00195663
  • 45.5% vs 27.2% wk 52 · n 268 · Phase 3 · secondary NCT00195663
  • 19.7% vs 22.2% wk 26 · n 274 · Phase 3 · secondary NCT00195663
  • 42.5% vs 22.2% wk 26 · n 268 · Phase 3 · secondary NCT00195663
  • 69.5% vs 57.1% wk 78 · n 105 · Phase 4 · secondary NCT00420927
  • 30.1% vs 57.1% wk 78 · n 259 · Phase 4 · secondary NCT00420927
  • 23.1% vs 40% wk 104 · n 39 · Phase 4 · secondary NCT01162421
  • 30.8% vs 20% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 30.8% vs 14.3% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 25.6% vs 22.9% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 28.2% vs 8.6% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 15.4% vs 2.9% wk 13 · n 39 · Phase 4 · secondary NCT01162421
—Not reported
DAS28-CRP remission38.5% vs 42.9%vs Standard of Carewk 104 · n 39NCT01162421
5 other results
  • 30.8% vs 34.3% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 35.9% vs 22.9% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 28.2% vs 31.4% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 35.9% vs 11.4% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 17.9% vs 8.6% wk 13 · n 39 · Phase 4 · secondary NCT01162421
—Not reported
HAQ-DI, change-0.6 vs -0.3−0.3 vs placebo40 mg every other week · wk 52 · n 204NCT00195702
22 other results
  • -0.6 vs -0.3 20 mg weekly · wk 52 · n 212 · Phase 3 · primary NCT00195702
  • -0.6 vs -0.2 40 mg every other week · wk 24 · n 204 · Phase 3 · secondary NCT00195702
  • -0.4 vs -0.1 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.4 vs -0.1 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.3 vs 0 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.2 vs 0 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.5 vs -0.3 40 mg · wk 12 · n 120 · Phase 2/3 · secondary NCT00538902
  • -0.4 vs -0.1 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.4 vs -0.1 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.2 vs 0 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.2 vs 0 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.4 vs -0.3 80 mg · wk 12 · n 120 · Phase 2/3 · secondary NCT00538902
  • -0.6 vs -0.2 20 mg weekly · wk 24 · n 212 · Phase 3 · secondary NCT00195702
  • -0.8 vs -0.8 wk 52 · n 191 · Phase 3 · secondary NCT00195663
  • -1.1 vs -0.8 wk 52 · n 213 · Phase 3 · secondary NCT00195663
  • -0.6 vs -0.7 wk 104 · n 454 · Phase 4 · secondary NCT01500278
  • -0.5 vs -0.6 wk 104 · n 38 · Phase 4 · secondary NCT01162421
  • -0.6 vs -0.6 wk 78 · n 38 · Phase 4 · secondary NCT01162421
  • -0.5 vs -0.6 wk 52 · n 38 · Phase 4 · secondary NCT01162421
  • -0.5 vs -0.5 wk 39 · n 38 · Phase 4 · secondary NCT01162421
  • -0.5 vs -0.3 wk 26 · n 38 · Phase 4 · secondary NCT01162421
  • -0.4 vs -0.4 wk 13 · n 38 · Phase 4 · secondary NCT01162421
—Not reported
Modified Sharp score, change0.1 vs 2.7−2.6 vs placebo40 mg every other week · wk 52 · n 183NCT00195702
15 other results
  • 0.8 vs 2.7 20 mg weekly · wk 52 · n 196 · Phase 3 · primary NCT00195702
  • 1.5 vs 2.4 wk 26 · n 148 · Phase 3 · primary NCT00870467
  • 3 vs 5.7 wk 52 · n 274 · Phase 3 · primary NCT00195663
  • 1.3 vs 5.7 wk 52 · n 268 · Phase 3 · primary NCT00195663
  • 0.7 vs 6.2 40 mg every other week · wk 520 · n 79 · Phase 3 · secondary NCT00195702
  • 0.1 vs 4.8 40 mg every other week · wk 416 · n 81 · Phase 3 · secondary NCT00195702
  • 0.3 vs 1.3 40 mg every other week · wk 24 · n 183 · Phase 3 · secondary NCT00195702
  • 2.6 vs 6.2 20 mg weekly, then 40 mg every other week · wk 520 · n 70 · Phase 3 · secondary NCT00195702
  • 1.2 vs 4.8 20 mg weekly, then 40 mg every other week · wk 416 · n 70 · Phase 3 · secondary NCT00195702
  • 0.6 vs 1.3 20 mg weekly · wk 24 · n 196 · Phase 3 · secondary NCT00195702
  • 5.5 vs 10.4 wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 1.9 vs 10.4 wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 0.0 vs 2.2 wk 104 · n 39 · Phase 4 · secondary NCT01162421
  • 0.2 vs 1.6 wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 0.0 vs 0.9 wk 26 · n 39 · Phase 4 · secondary NCT01162421
—Not reported

ACR20

adalimumab
63.3% vs 29.5%+33.8 vs placebo40 mg every other week · wk 24 · n 207NCT00195702
28 other results
  • 50.3% vs 33.9% 40 mg every other week · wk 12 · n 159 · Phase 3 · primary NCT00647270
  • 57% vs 35% 40 mg · wk 12 · n 121 · Phase 2/3 · primary NCT00538902
  • 47.3% vs 33.9% 80 mg monthly · wk 12 · n 205 · Phase 3 · primary NCT00647270
  • 51.2% vs 35% 80 mg · wk 12 · n 121 · Phase 2/3 · primary NCT00538902
  • 60.8% vs 29.5% 20 mg weekly · wk 24 · n 212 · Phase 3 · primary NCT00195702
  • 58.9% vs 24% 40 mg every other week · wk 52 · n 207 · Phase 3 · secondary NCT00195702
  • 54.7% vs 24% 20 mg weekly · wk 52 · n 212 · Phase 3 · secondary NCT00195702
  • 75.4% vs 56.4% wk 26 · n 171 · Phase 3 · secondary NCT00870467
  • 49.3% vs 56% wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 69.4% vs 56% wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 50% vs 59.9% wk 76 · n 274 · Phase 3 · secondary NCT00195663
  • 69% vs 59.9% wk 76 · n 268 · Phase 3 · secondary NCT00195663
  • 54.4% vs 62.6% wk 52 · n 274 · Phase 3 · secondary NCT00195663
  • 72.8% vs 62.6% wk 52 · n 268 · Phase 3 · secondary NCT00195663
  • 53.3% vs 61.5% wk 26 · n 274 · Phase 3 · secondary NCT00195663
  • 68.7% vs 61.5% wk 26 · n 268 · Phase 3 · secondary NCT00195663
  • 69.2% vs 71.4% wk 12 · n 454 · Phase 4 · primary NCT01500278
  • 84.8% vs 80.4% wk 78 · n 105 · Phase 4 · secondary NCT00420927
  • 66.4% vs 80.4% wk 78 · n 259 · Phase 4 · secondary NCT00420927
  • 64.5% vs 60.8% wk 6 · n 454 · Phase 4 · secondary NCT01500278
  • 68% vs 68% 40 mg every other week · wk 24 · n 50 · Phase 2 · secondary NCT01712178
  • 62% vs 68% 40 mg every other week · wk 12 · n 50 · Phase 2 · secondary NCT01712178
  • 46.2% vs 65.7% wk 104 · n 39 · Phase 4 · secondary NCT01162421
  • 51.3% vs 65.7% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 56.4% vs 68.6% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 66.7% vs 60% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 64.1% vs 37.1% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 69.2% vs 57.1% wk 13 · n 39 · Phase 4 · secondary NCT01162421
adalimumab-adbm (Cyltezo)
—Not reported

ACR50

adalimumab
41.2% vs 45.9%vs Methotrexatewk 52 · n 274NCT00195663
19 other results
  • 61.6% vs 45.9% wk 52 · n 268 · Phase 3 · primary NCT00195663
  • 64.3% vs 38.7% wk 26 · n 171 · Phase 3 · secondary NCT00870467
  • 36.9% vs 42.8% wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 59% vs 42.8% wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 41.6% vs 44.4% wk 76 · n 274 · Phase 3 · secondary NCT00195663
  • 60.1% vs 44.4% wk 76 · n 268 · Phase 3 · secondary NCT00195663
  • 35% vs 40.5% wk 26 · n 274 · Phase 3 · secondary NCT00195663
  • 58.6% vs 40.5% wk 26 · n 268 · Phase 3 · secondary NCT00195663
  • 78.1% vs 69.6% wk 78 · n 105 · Phase 4 · secondary NCT00420927
  • 46.3% vs 69.6% wk 78 · n 259 · Phase 4 · secondary NCT00420927
  • 48% vs 50% 40 mg every other week · wk 24 · n 50 · Phase 2 · secondary NCT01712178
  • 36% vs 40% 40 mg every other week · wk 12 · n 50 · Phase 2 · secondary NCT01712178
  • 33.3% vs 42.9% wk 104 · n 39 · Phase 4 · secondary NCT01162421
  • 38.5% vs 45.7% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 43.6% vs 34.3% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 48.7% vs 40% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 43.6% vs 22.9% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 38.5% vs 22.9% wk 13 · n 39 · Phase 4 · secondary NCT01162421
  • 64.7% vs 51.6% wk 12 · n 17 · Phase 2 · secondary NCT03823391
adalimumab-adbm (Cyltezo)
—Not reported

ACR70

adalimumab
47.4% vs 22.7%+24.7 vs placebowk 26 · n 171NCT00870467
16 other results
  • 28.1% vs 28.4% wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 46.6% vs 28.4% wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 28.8% vs 29.2% wk 76 · n 274 · Phase 3 · secondary NCT00195663
  • 47.4% vs 29.2% wk 76 · n 268 · Phase 3 · secondary NCT00195663
  • 25.9% vs 27.2% wk 52 · n 274 · Phase 3 · secondary NCT00195663
  • 45.5% vs 27.2% wk 52 · n 268 · Phase 3 · secondary NCT00195663
  • 19.7% vs 22.2% wk 26 · n 274 · Phase 3 · secondary NCT00195663
  • 42.5% vs 22.2% wk 26 · n 268 · Phase 3 · secondary NCT00195663
  • 69.5% vs 57.1% wk 78 · n 105 · Phase 4 · secondary NCT00420927
  • 30.1% vs 57.1% wk 78 · n 259 · Phase 4 · secondary NCT00420927
  • 23.1% vs 40% wk 104 · n 39 · Phase 4 · secondary NCT01162421
  • 30.8% vs 20% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 30.8% vs 14.3% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 25.6% vs 22.9% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 28.2% vs 8.6% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 15.4% vs 2.9% wk 13 · n 39 · Phase 4 · secondary NCT01162421
adalimumab-adbm (Cyltezo)
—Not reported

DAS28-CRP remission

adalimumab
38.5% vs 42.9%vs Standard of Carewk 104 · n 39NCT01162421
5 other results
  • 30.8% vs 34.3% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 35.9% vs 22.9% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 28.2% vs 31.4% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 35.9% vs 11.4% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 17.9% vs 8.6% wk 13 · n 39 · Phase 4 · secondary NCT01162421
adalimumab-adbm (Cyltezo)
—Not reported

HAQ-DI, change

adalimumab
-0.6 vs -0.3−0.3 vs placebo40 mg every other week · wk 52 · n 204NCT00195702
22 other results
  • -0.6 vs -0.3 20 mg weekly · wk 52 · n 212 · Phase 3 · primary NCT00195702
  • -0.6 vs -0.2 40 mg every other week · wk 24 · n 204 · Phase 3 · secondary NCT00195702
  • -0.4 vs -0.1 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.4 vs -0.1 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.3 vs 0 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.2 vs 0 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.5 vs -0.3 40 mg · wk 12 · n 120 · Phase 2/3 · secondary NCT00538902
  • -0.4 vs -0.1 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.4 vs -0.1 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.2 vs 0 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.2 vs 0 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.4 vs -0.3 80 mg · wk 12 · n 120 · Phase 2/3 · secondary NCT00538902
  • -0.6 vs -0.2 20 mg weekly · wk 24 · n 212 · Phase 3 · secondary NCT00195702
  • -0.8 vs -0.8 wk 52 · n 191 · Phase 3 · secondary NCT00195663
  • -1.1 vs -0.8 wk 52 · n 213 · Phase 3 · secondary NCT00195663
  • -0.6 vs -0.7 wk 104 · n 454 · Phase 4 · secondary NCT01500278
  • -0.5 vs -0.6 wk 104 · n 38 · Phase 4 · secondary NCT01162421
  • -0.6 vs -0.6 wk 78 · n 38 · Phase 4 · secondary NCT01162421
  • -0.5 vs -0.6 wk 52 · n 38 · Phase 4 · secondary NCT01162421
  • -0.5 vs -0.5 wk 39 · n 38 · Phase 4 · secondary NCT01162421
  • -0.5 vs -0.3 wk 26 · n 38 · Phase 4 · secondary NCT01162421
  • -0.4 vs -0.4 wk 13 · n 38 · Phase 4 · secondary NCT01162421
adalimumab-adbm (Cyltezo)
—Not reported

Modified Sharp score, change

adalimumab
0.1 vs 2.7−2.6 vs placebo40 mg every other week · wk 52 · n 183NCT00195702
15 other results
  • 0.8 vs 2.7 20 mg weekly · wk 52 · n 196 · Phase 3 · primary NCT00195702
  • 1.5 vs 2.4 wk 26 · n 148 · Phase 3 · primary NCT00870467
  • 3 vs 5.7 wk 52 · n 274 · Phase 3 · primary NCT00195663
  • 1.3 vs 5.7 wk 52 · n 268 · Phase 3 · primary NCT00195663
  • 0.7 vs 6.2 40 mg every other week · wk 520 · n 79 · Phase 3 · secondary NCT00195702
  • 0.1 vs 4.8 40 mg every other week · wk 416 · n 81 · Phase 3 · secondary NCT00195702
  • 0.3 vs 1.3 40 mg every other week · wk 24 · n 183 · Phase 3 · secondary NCT00195702
  • 2.6 vs 6.2 20 mg weekly, then 40 mg every other week · wk 520 · n 70 · Phase 3 · secondary NCT00195702
  • 1.2 vs 4.8 20 mg weekly, then 40 mg every other week · wk 416 · n 70 · Phase 3 · secondary NCT00195702
  • 0.6 vs 1.3 20 mg weekly · wk 24 · n 196 · Phase 3 · secondary NCT00195702
  • 5.5 vs 10.4 wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 1.9 vs 10.4 wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 0.0 vs 2.2 wk 104 · n 39 · Phase 4 · secondary NCT01162421
  • 0.2 vs 1.6 wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 0.0 vs 0.9 wk 26 · n 39 · Phase 4 · secondary NCT01162421
adalimumab-adbm (Cyltezo)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

adalimumab-adbm (Cyltezo): registry results are on file for Rheumatoid Arthritis, but their comparison mappings are not yet available.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. adalimumab: 4 of 4 rows · adalimumab-adbm (Cyltezo): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumab
Dropout rate
23.2%40 mg every other weeka
NCT00195702 · Phase 3
show 50 more results
—40 mg every other week
NCT00195702 · Phase 3
20.8%20 mg weekly
NCT00195702 · Phase 3
—20 mg weekly, then 40 mg every other week
NCT00195702 · Phase 3
—maximum tolerated dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
—reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
24.8%40 mg Eow
NCT02198651 · Phase 4 · registry result, not featured evidence
—40 mg Eow
NCT02198651 · Phase 4 · registry result, not featured evidence
—Adalimumab Tapering
NCT02198651 · Phase 4 · registry result, not featured evidence
66.7%
NCT02451748 · Phase 4 · registry result, not featured evidence · combination
—
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
32.5%
NCT01162421 · Phase 4 · registry result, not featured evidence
10.3%high dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
12.3%low dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
—ADA+MTX/ADA+MTX (Arm 2)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
—ADA+MTX/OL ADA+MTX (Arm 3)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
5.9%
NCT03172325 · Phase 3 · registry result, not featured evidence
9.2%20 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
6.1%10 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
7%5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
15.3%2.5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
39.4%Adalimumab
NCT00195663 · Phase 3 · registry result, not featured evidence
26.9%Adalimumab + Methotrexate
NCT00195663 · Phase 3 · registry result, not featured evidence · combination
36%
NCT00690573 · Phase 3 · registry result, not featured evidence
9.4%DB Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
—DB Adalimumab/OL Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
—DB Adalimumab/RE OL Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
62.1%
NCT00195650 · Phase 3 · registry result, not featured evidence
5%40 mg/0.8 mL
NCT01231321 · Phase 3 · registry result, not featured evidence
8.2%40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
—40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
—40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
11.2%80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
—80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
—80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
22.7%40 mg or 80 mg every other week
NCT00603993 · Phase 3 · registry result, not featured evidence
47.6%40 mg every other week
NCT00235872 · Phase 3 · registry result, not featured evidence
1.7%40 mg
NCT00538902 · Phase 2/3 · registry result, not featured evidence
—40 mg EOW
NCT00538902 · Phase 2/3 · registry result, not featured evidence
4.1%80 mg
NCT00538902 · Phase 2/3 · registry result, not featured evidence
—80 mg EOW
NCT00538902 · Phase 2/3 · registry result, not featured evidence
0%Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
—Period 1: Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
—Period 2: Adalimumab / Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
2%40 mg
NCT02565810 · Phase 2 · registry result, not featured evidence
9.1%Current Formulation for 24 Weeks,
NCT01752855 · Phase 2 · registry result, not featured evidence
2.3%New Formulation for 48 Weeks
NCT01752855 · Phase 2 · registry result, not featured evidence
2%40 mg every other week
NCT01712178 · Phase 2 · registry result, not featured evidence
—Current Formulation Adalimumab
NCT01561313 · Phase 2 · registry result, not featured evidence
—New Formulation of Adalimumab
NCT01561313 · Phase 2 · registry result, not featured evidence
64%40 mg Eow
NCT00235833 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—40 mg every other weeka
NCT00195702 · Phase 3
show 50 more results
—40 mg every other week
NCT00195702 · Phase 3
—20 mg weekly
NCT00195702 · Phase 3
—20 mg weekly, then 40 mg every other week
NCT00195702 · Phase 3
—maximum tolerated dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
—reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
1.3%40 mg Eow
NCT02198651 · Phase 4 · registry result, not featured evidence
—40 mg Eow
NCT02198651 · Phase 4 · registry result, not featured evidence
—Adalimumab Tapering
NCT02198651 · Phase 4 · registry result, not featured evidence
—
NCT02451748 · Phase 4 · registry result, not featured evidence · combination
—
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
12.5%
NCT01162421 · Phase 4 · registry result, not featured evidence
3.9%high dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
4.5%low dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
—ADA+MTX/ADA+MTX (Arm 2)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
—ADA+MTX/OL ADA+MTX (Arm 3)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
2.9%
NCT03172325 · Phase 3 · registry result, not featured evidence
3.1%20 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
2%10 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
0%5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
3.1%2.5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
9.9%Adalimumab
NCT00195663 · Phase 3 · registry result, not featured evidence
11.9%Adalimumab + Methotrexate
NCT00195663 · Phase 3 · registry result, not featured evidence · combination
—
NCT00690573 · Phase 3 · registry result, not featured evidence
—DB Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
—DB Adalimumab/OL Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
—DB Adalimumab/RE OL Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
22.9%
NCT00195650 · Phase 3 · registry result, not featured evidence
3%40 mg/0.8 mL
NCT01231321 · Phase 3 · registry result, not featured evidence
4.4%40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
—40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
—40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
3.4%80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
—80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
—80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
—40 mg or 80 mg every other week
NCT00603993 · Phase 3 · registry result, not featured evidence
11%40 mg every other week
NCT00235872 · Phase 3 · registry result, not featured evidence
1.7%40 mg
NCT00538902 · Phase 2/3 · registry result, not featured evidence
—40 mg EOW
NCT00538902 · Phase 2/3 · registry result, not featured evidence
2.5%80 mg
NCT00538902 · Phase 2/3 · registry result, not featured evidence
—80 mg EOW
NCT00538902 · Phase 2/3 · registry result, not featured evidence
—Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
—Period 1: Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
—Period 2: Adalimumab / Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
—40 mg
NCT02565810 · Phase 2 · registry result, not featured evidence
0%Current Formulation for 24 Weeks,
NCT01752855 · Phase 2 · registry result, not featured evidence
2.3%New Formulation for 48 Weeks
NCT01752855 · Phase 2 · registry result, not featured evidence
2%40 mg every other week
NCT01712178 · Phase 2 · registry result, not featured evidence
—Current Formulation Adalimumab
NCT01561313 · Phase 2 · registry result, not featured evidence
—New Formulation of Adalimumab
NCT01561313 · Phase 2 · registry result, not featured evidence
—40 mg Eow
NCT00235833 · Phase 2 · registry result, not featured evidence
Serious AEs
13%40 mg every other weeka
NCT00195702 · Phase 3
show 50 more results
—40 mg every other week
NCT00195702 · Phase 3
16%20 mg weekly
NCT00195702 · Phase 3
—20 mg weekly, then 40 mg every other week
NCT00195702 · Phase 3
7.4%maximum tolerated dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
4.5%reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
2.7%40 mg Eow
NCT02198651 · Phase 4 · registry result, not featured evidence
7.7%40 mg Eow
NCT02198651 · Phase 4 · registry result, not featured evidence
1%Adalimumab Tapering
NCT02198651 · Phase 4 · registry result, not featured evidence
0%
NCT02451748 · Phase 4 · registry result, not featured evidence · combination
13%
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
10.3%
NCT01162421 · Phase 4 · registry result, not featured evidence
7.1%high dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
3.9%low dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
11.4%ADA+MTX/ADA+MTX (Arm 2)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
6.9%ADA+MTX/OL ADA+MTX (Arm 3)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
2.9%
NCT03172325 · Phase 3 · registry result, not featured evidence
7.1%20 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
3%10 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
2%5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
5.1%2.5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
23.7%Adalimumab
NCT00195663 · Phase 3 · registry result, not featured evidence
20.9%Adalimumab + Methotrexate
NCT00195663 · Phase 3 · registry result, not featured evidence · combination
24%
NCT00690573 · Phase 3 · registry result, not featured evidence
4.1%DB Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
—DB Adalimumab/OL Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
—DB Adalimumab/RE OL Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
51.1%
NCT00195650 · Phase 3 · registry result, not featured evidence
1%40 mg/0.8 mL
NCT01231321 · Phase 3 · registry result, not featured evidence
—40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
4.9%40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
3.3%40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
—80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
6.4%80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
1.9%80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
22.7%40 mg or 80 mg every other week
NCT00603993 · Phase 3 · registry result, not featured evidence
35.9%40 mg every other week
NCT00235872 · Phase 3 · registry result, not featured evidence
—40 mg
NCT00538902 · Phase 2/3 · registry result, not featured evidence
0%40 mg EOW
NCT00538902 · Phase 2/3 · registry result, not featured evidence
—80 mg
NCT00538902 · Phase 2/3 · registry result, not featured evidence
2.5%80 mg EOW
NCT00538902 · Phase 2/3 · registry result, not featured evidence
—Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
0%Period 1: Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
12.5%Period 2: Adalimumab / Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
0%40 mg
NCT02565810 · Phase 2 · registry result, not featured evidence
2.3%Current Formulation for 24 Weeks,
NCT01752855 · Phase 2 · registry result, not featured evidence
4.5%New Formulation for 48 Weeks
NCT01752855 · Phase 2 · registry result, not featured evidence
0%40 mg every other week
NCT01712178 · Phase 2 · registry result, not featured evidence
0%Current Formulation Adalimumab
NCT01561313 · Phase 2 · registry result, not featured evidence
0%New Formulation of Adalimumab
NCT01561313 · Phase 2 · registry result, not featured evidence
40%40 mg Eow
NCT00235833 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
40 mg every other weeka
injection site pain 17.9% (placebo 21.5%)
upper respiratory tract infection 16.9% (placebo 11%)
headache 11.6% (placebo 5%)
NCT00195702 · Phase 3
show 40 more results
20 mg weekly
injection site pain 17.5% (placebo 21.5%)
upper respiratory tract infection 16.5% (placebo 11%)
headache 13.2% (placebo 5%)
NCT00195702 · Phase 3
maximum tolerated dose
liver function test abnormal 8.8%
abdominal pain upper 2.9%
dry mouth 1.5%
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
reduced dose
dry mouth 3%
alanine aminotransferase increased 1.5%
cough 1.5%
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
40 mg Eow
cough 2.7% (placebo 5%)
nasopharyngitis 2.7% (placebo 20%)
urinary tract infection 1.4% (placebo 0%)
NCT02198651 · Phase 4 · registry result, not featured evidence
40 mg Eow
nasopharyngitis 10.3% (placebo 20%)
upper respiratory tract infection 7.7% (placebo 0%)
hepatic enzyme increased 5.1% (placebo 0%)
NCT02198651 · Phase 4 · registry result, not featured evidence
nasopharyngitis 15.7% (placebo 20%)
arthralgia 5.9% (placebo 0%)
influenza 4.9% (placebo 10%)
NCT02198651 · Phase 4 · registry result, not featured evidence
nasopharyngitis 15.3%
headache 10.7%
upper respiratory tract infection 10.3%
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
rheumatoid arthritis 25.6%
nasopharyngitis 20.5%
alanine aminotransferase increased 15.4%
NCT01162421 · Phase 4 · registry result, not featured evidence
high dose
nausea 10.3%
upper respiratory tract infection 7.7%
urinary tract infection 7.1%
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
low dose
nausea 9.7%
fatigue 9.1%
upper respiratory tract infection 9.1%
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
cough 6.7% (placebo 3.6%)
influenza 5.7% (placebo 2.7%)
nasopharyngitis 5.7% (placebo 3.6%)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
upper respiratory tract infection 11.2% (placebo 6.3%)
nasopharyngitis 8.9% (placebo 3.6%)
alanine aminotransferase increased 6.2% (placebo 2.7%)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
injection site reaction 8.8%
headache 5.9%
nausea 5.9%
NCT03172325 · Phase 3 · registry result, not featured evidence
20 mg MTX
nasopharyngitis 11.2%
headache 9.2%
alopecia 8.2%
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
10 mg MTX
nausea 13.1%
alopecia 6.1%
diarrhoea 6.1%
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
5 mg MTX
diarrhoea 6%
headache 6%
nasopharyngitis 6%
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
2.5 mg MTX
nausea 7.1%
arthralgia 6.1%
abdominal pain upper 4.1%
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 22.6%
headache 21.5%
nausea 17.5%
NCT00195663 · Phase 3 · registry result, not featured evidence
nasopharyngitis 30.2%
headache 20.5%
upper respiratory tract infection 18.7%
NCT00195663 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 56%
upper respiratory tract infection 56%
influenza 32%
NCT00690573 · Phase 3 · registry result, not featured evidence
nasopharyngitis 15.2% (placebo 16.6%)
hepatic function abnormal 8.2% (placebo 5.5%)
alanine aminotransferase increased 7.6% (placebo 3.7%)
NCT00870467 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 46.3%
rheumatoid arthritis 25.4%
sinusitis 24.9%
NCT00195650 · Phase 3 · registry result, not featured evidence
40 mg/0.8 mL
nasopharyngitis 4%
respiratory disorder 4%
headache 3%
NCT01231321 · Phase 3 · registry result, not featured evidence
40 mg every other week
nausea 5.5% (placebo 5.3%)
headache 4.9% (placebo 5.3%)
nasopharyngitis 4.9% (placebo 5.3%)
NCT00647270 · Phase 3 · registry result, not featured evidence
40 mg every other week
nasopharyngitis 6.6% (placebo 5.3%)
upper respiratory tract infection 2.6% (placebo 7%)
cough 0% (placebo 5.3%)
NCT00647270 · Phase 3 · registry result, not featured evidence
80 mg monthly
upper respiratory tract infection 3.2% (placebo 7%)
nasopharyngitis 2.7% (placebo 5.3%)
cough 0% (placebo 5.3%)
NCT00647270 · Phase 3 · registry result, not featured evidence
80 mg monthly
nausea 6.2% (placebo 5.3%)
upper respiratory tract infection 5.2% (placebo 7%)
headache 4.7% (placebo 5.3%)
NCT00647270 · Phase 3 · registry result, not featured evidence
40 mg or 80 mg every other week
nasopharyngitis 60.2%
adverse drug reaction 29.5%
antinuclear antibody positive 15.9%
NCT00603993 · Phase 3 · registry result, not featured evidence
40 mg every other week
nasopharyngitis 45%
adverse drug reaction 23.6%
dna antibody positive 16.2%
NCT00235872 · Phase 3 · registry result, not featured evidence
40 mg EOW
upper respiratory tract infection 14% (placebo 11.7%)
injection site pruritus 5.8% (placebo 0%)
nasopharyngitis 5.8% (placebo 6.7%)
NCT00538902 · Phase 2/3 · registry result, not featured evidence
80 mg EOW
upper respiratory tract infection 12.4% (placebo 11.7%)
nasopharyngitis 7.4% (placebo 6.7%)
injection site pruritus 4.1% (placebo 0%)
NCT00538902 · Phase 2/3 · registry result, not featured evidence
urinary tract infection 11.8%
abdominal discomfort 5.9%
arthralgia 5.9%
NCT03823391 · Phase 2 · registry result, not featured evidence
nasopharyngitis 12.5%
bronchitis 6.3%
drug hypersensitivity 6.3%
NCT03823391 · Phase 2 · registry result, not featured evidence
40 mg
nasopharyngitis 8.2%
NCT02565810 · Phase 2 · registry result, not featured evidence
nasopharyngitis 15.9%
rheumatoid arthritis 9.1%
upper respiratory tract infection 9.1%
NCT01752855 · Phase 2 · registry result, not featured evidence
nasopharyngitis 13.6%
cystitis 9.1%
upper respiratory tract infection 9.1%
NCT01752855 · Phase 2 · registry result, not featured evidence
40 mg every other week
nasopharyngitis 10%
cystitis 8%
nausea 8%
NCT01712178 · Phase 2 · registry result, not featured evidence
pharyngitis 1.6%
rash erythematous 1.6%
protein urine present 0%
NCT01561313 · Phase 2 · registry result, not featured evidence
protein urine present 1.6%
pharyngitis 0%
rash erythematous 0%
NCT01561313 · Phase 2 · registry result, not featured evidence
40 mg Eow
nasopharyngitis 60%
diarrhoea 24%
pruritus 20%
NCT00235833 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab

ACR20 63.3% (n=207) vs 29.5% (n=200) placebo @ 24wk40 mg every other week
responder rate · % of participants
NCT00195702 · Phase 3 · converted to % from 131 Participants as posted
show 28 more results
58.9% (n=207) vs 24% (n=200) placebo @ 52wk*40 mg every other week
NCT00195702 · Phase 3 · converted to % from 122 Participants as posted
50.3% (n=159) vs 33.9% (n=56) placebo @ 12wk*40 mg every other week
Responders
NCT00647270 · Phase 3 · registry result, not featured evidence · converted to % from 80 participants as posted
57% (n=121) vs 35% (n=60) placebo @ 12wk*40 mg
NCT00538902 · Phase 2/3 · registry result, not featured evidence · converted to % from 69 Participants as posted
62% (n=50) vs 68% (n=50) Adalimumab @ 12wk40 mg every other week
NCT01712178 · Phase 2 · registry result, not featured evidence
68% (n=50) vs 68% (n=50) Adalimumab @ 24wk40 mg every other week
NCT01712178 · Phase 2 · registry result, not featured evidence
47.3% (n=205) vs 33.9% (n=56) placebo @ 12wk*80 mg monthly
Responders
NCT00647270 · Phase 3 · registry result, not featured evidence · converted to % from 97 participants as posted
51.2% (n=121) vs 35% (n=60) placebo @ 12wk*80 mg
NCT00538902 · Phase 2/3 · registry result, not featured evidence · converted to % from 62 Participants as posted
60.8% (n=212) vs 29.5% (n=200) placebo @ 24wk*20 mg weekly
NCT00195702 · Phase 3 · converted to % from 129 Participants as posted
54.7% (n=212) vs 24% (n=200) placebo @ 52wk*20 mg weekly
NCT00195702 · Phase 3 · converted to % from 116 Participants as posted
69.2% (n=454) vs 71.4% (n=454) ADA+MTX @ 12wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
64.5% (n=454) vs 60.8% (n=454) ADA+MTX @ 6wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
69.2% (n=39) vs 57.1% (n=35) Standard of Care @ 13wk
NCT01162421 · Phase 4 · registry result, not featured evidence
64.1% (n=39) vs 37.1% (n=35) Standard of Care @ 26wk
NCT01162421 · Phase 4 · registry result, not featured evidence
66.7% (n=39) vs 60% (n=35) Standard of Care @ 39wk
NCT01162421 · Phase 4 · registry result, not featured evidence
56.4% (n=39) vs 68.6% (n=35) Standard of Care @ 52wk
NCT01162421 · Phase 4 · registry result, not featured evidence
51.3% (n=39) vs 65.7% (n=35) Standard of Care @ 78wk
NCT01162421 · Phase 4 · registry result, not featured evidence
46.2% (n=39) vs 65.7% (n=35) Standard of Care @ 104wk
NCT01162421 · Phase 4 · registry result, not featured evidence
84.8% (n=105) vs 80.4% (n=112) placebo @ 78wk*
NCT00420927 · Phase 4 · registry result, not featured evidence · combination · converted to % from 89 Participants as posted
66.4% (n=259) vs 80.4% (n=112) placebo @ 78wk*
NCT00420927 · Phase 4 · registry result, not featured evidence · combination · converted to % from 172 Participants as posted
53.3% (n=274) vs 61.5% (n=257) Methotrexate @ 26wk*
NCT00195663 · Phase 3 · registry result, not featured evidence · converted to % from 146 participants as posted
68.7% (n=268) vs 61.5% (n=257) Methotrexate @ 26wk*
NCT00195663 · Phase 3 · registry result, not featured evidence · combination · converted to % from 184 participants as posted
54.4% (n=274) vs 62.6% (n=257) Methotrexate @ 52wk*
NCT00195663 · Phase 3 · registry result, not featured evidence · converted to % from 149 participants as posted
72.8% (n=268) vs 62.6% (n=257) Methotrexate @ 52wk*
NCT00195663 · Phase 3 · registry result, not featured evidence · combination · converted to % from 195 participants as posted
50% (n=274) vs 59.9% (n=257) Methotrexate @ 76wk*
NCT00195663 · Phase 3 · registry result, not featured evidence · converted to % from 137 participants as posted
69% (n=268) vs 59.9% (n=257) Methotrexate @ 76wk*
NCT00195663 · Phase 3 · registry result, not featured evidence · combination · converted to % from 185 participants as posted
49.3% (n=274) vs 56% (n=257) Methotrexate @ 104wk*
NCT00195663 · Phase 3 · registry result, not featured evidence · converted to % from 135 participants as posted
69.4% (n=268) vs 56% (n=257) Methotrexate @ 104wk*
NCT00195663 · Phase 3 · registry result, not featured evidence · combination · converted to % from 186 participants as posted
75.4% (n=171) vs 56.4% (n=163) placebo @ 26wk*
NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 129 participants as posted
Modified Sharp 0.1 vs 2.7 placebo score @ 52wk40 mg every other week
absolute change · score
NCT00195702 · Phase 3
show 15 more results
0.3 vs 1.3 placebo score @ 24wk40 mg every other week
NCT00195702 · Phase 3
0.14 vs 4.83 placebo score @ 416wk40 mg every other week
NCT00195702 · Phase 3
0.72 vs 6.18 placebo score @ 520wk40 mg every other week
NCT00195702 · Phase 3
0.8 vs 2.7 placebo score @ 52wk20 mg weekly
NCT00195702 · Phase 3
0.6 vs 1.3 placebo score @ 24wk20 mg weekly
NCT00195702 · Phase 3
1.16 vs 4.83 placebo score @ 416wk20 mg weekly, then 40 mg every other week
NCT00195702 · Phase 3
2.6 vs 6.18 placebo score @ 520wk20 mg weekly, then 40 mg every other week
NCT00195702 · Phase 3
0.02 vs 0.88 Standard of Care score @ 26wk
NCT01162421 · Phase 4 · registry result, not featured evidence
0.16 vs 1.62 Standard of Care score @ 52wk
NCT01162421 · Phase 4 · registry result, not featured evidence
0.01 vs 2.24 Standard of Care score @ 104wk
NCT01162421 · Phase 4 · registry result, not featured evidence
3 vs 5.7 Methotrexate score @ 52wk
NCT00195663 · Phase 3 · registry result, not featured evidence
1.3 vs 5.7 Methotrexate score @ 52wk
NCT00195663 · Phase 3 · registry result, not featured evidence · combination
5.5 vs 10.4 Methotrexate score @ 104wk
NCT00195663 · Phase 3 · registry result, not featured evidence
1.9 vs 10.4 Methotrexate score @ 104wk
NCT00195663 · Phase 3 · registry result, not featured evidence · combination
1.5 vs 2.4 placebo score @ 26wk
NCT00870467 · Phase 3 · registry result, not featured evidence
HAQ-DI -0.56 vs -0.24 placebo score @ 24wk40 mg every other week
absolute change · score
NCT00195702 · Phase 3
show 22 more results
-0.59 vs -0.25 placebo score @ 52wk40 mg every other week
NCT00195702 · Phase 3
-0.41 vs -0.11 placebo score @ 12wk40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
-0.4 vs -0.12 placebo score @ 12wk40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
-0.26 vs 0 placebo score @ 12wk40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
-0.24 vs 0 placebo score @ 12wk40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
-0.5 vs -0.3 placebo score @ 12wk40 mg
NCT00538902 · Phase 2/3 · registry result, not featured evidence
-0.39 vs -0.11 placebo score @ 12wk80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
-0.37 vs -0.12 placebo score @ 12wk80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
-0.24 vs 0 placebo score @ 12wk80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
-0.21 vs 0 placebo score @ 12wk80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
-0.4 vs -0.3 placebo score @ 12wk80 mg
NCT00538902 · Phase 2/3 · registry result, not featured evidence
-0.6 vs -0.24 placebo score @ 24wk20 mg weekly
NCT00195702 · Phase 3
-0.61 vs -0.25 placebo score @ 52wk20 mg weekly
NCT00195702 · Phase 3
-0.62 vs -0.72 ADA+MTX score @ 104wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
-0.38 vs -0.41 Standard of Care score @ 13wk
NCT01162421 · Phase 4 · registry result, not featured evidence
-0.46 vs -0.29 Standard of Care score @ 26wk
NCT01162421 · Phase 4 · registry result, not featured evidence
-0.5 vs -0.52 Standard of Care score @ 39wk
NCT01162421 · Phase 4 · registry result, not featured evidence
-0.5 vs -0.6 Standard of Care score @ 52wk
NCT01162421 · Phase 4 · registry result, not featured evidence
-0.55 vs -0.6 Standard of Care score @ 78wk
NCT01162421 · Phase 4 · registry result, not featured evidence
-0.53 vs -0.61 Standard of Care score @ 104wk
NCT01162421 · Phase 4 · registry result, not featured evidence
-0.8 vs -0.8 Methotrexate score @ 52wk
NCT00195663 · Phase 3 · registry result, not featured evidence
-1.1 vs -0.8 Methotrexate score @ 52wk
NCT00195663 · Phase 3 · registry result, not featured evidence · combination
Sustained 8.7% (n=207) vs 1.5% (n=200) placebo40 mg every other week
responder rate · % of participants
NCT00195702 · Phase 3 · converted to % from 18 Participants as posted
show 1 more result
9.4% (n=212) vs 1.5% (n=200) placebo*20 mg weekly
NCT00195702 · Phase 3 · converted to % from 20 Participants as posted
Modified Sharp 0.09 vs 2.66 placebo score @ 52wk40 mg every other week
absolute change · score
Actual progression during study
NCT00195702 · Phase 3
show 1 more result
0.77 vs 2.66 placebo score @ 52wk20 mg weekly
Actual progression during study
NCT00195702 · Phase 3
SDAI Remission 29.6% (n=98) @ 26wk20 mg MTX
responder rate · % of participants
No placebo or comparator arm
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
show 7 more results
28.3% (n=99) @ 26wk10 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
22% (n=100) @ 26wk5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
11.2% (n=98) @ 26wk2.5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
37.9% (n=66) @ 48wk*maximum tolerated dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 25 Participants as posted
44.3% (n=61) @ 48wk*reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 27 Participants as posted
39.7% (n=58) @ 48wk*maximum tolerated dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 23 Participants as posted
44.3% (n=61) @ 48wk*reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 27 Participants as posted
ACR20 79.6% (n=98) @ 26wk20 mg MTX
responder rate · % of participants
No placebo or comparator arm
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
show 13 more results
76.8% (n=99) @ 26wk10 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
74% (n=100) @ 26wk5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
67.3% (n=98) @ 26wk2.5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
69.1% (n=68) @ 48wk*maximum tolerated dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 47 Participants as posted
71.2% (n=66) @ 48wk*reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 47 Participants as posted
97% (n=133) @ 52wk*
NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 129 participants as posted
80% (n=5) @ 52wk*
NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 4 participants as posted
78.6% (n=238) @ 520wk*
NCT00195650 · Phase 3 · registry result, not featured evidence · converted to % from 187 participants as posted
77.9% (n=516) @ 260wk*
NCT00195650 · Phase 3 · registry result, not featured evidence · converted to % from 402 participants as posted
72.7% (n=44) @ 36wk
NCT01752855 · Phase 2 · registry result, not featured evidence
76.7% (n=44) @ 36wk
NCT01752855 · Phase 2 · registry result, not featured evidence
74.4% (n=44) @ 48wk
NCT01752855 · Phase 2 · registry result, not featured evidence
80% (n=44) @ 48wk
NCT01752855 · Phase 2 · registry result, not featured evidence
ACR50 62.2% (n=98) @ 26wk20 mg MTX
responder rate · % of participants
No placebo or comparator arm
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
show 15 more results
53.5% (n=99) @ 26wk10 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
51% (n=100) @ 26wk5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
45.9% (n=98) @ 26wk2.5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
52.9% (n=68) @ 48wk*maximum tolerated dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 36 Participants as posted
57.6% (n=66) @ 48wk*reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 38 Participants as posted
29.8% (n=154) @ 24wklow dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
37.66% (n=155) @ 24wkhigh dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
88% (n=133) @ 52wk*
NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 117 participants as posted
40% (n=5) @ 52wk*
NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 2 participants as posted
55.5% (n=238) @ 520wk*
NCT00195650 · Phase 3 · registry result, not featured evidence · converted to % from 132 participants as posted
54.1% (n=516) @ 260wk*
NCT00195650 · Phase 3 · registry result, not featured evidence · converted to % from 279 participants as posted
50% (n=44) @ 36wk
NCT01752855 · Phase 2 · registry result, not featured evidence
51.2% (n=44) @ 36wk
NCT01752855 · Phase 2 · registry result, not featured evidence
53.5% (n=44) @ 48wk
NCT01752855 · Phase 2 · registry result, not featured evidence
57.5% (n=44) @ 48wk
NCT01752855 · Phase 2 · registry result, not featured evidence
ACR70 45.9% (n=98) @ 26wk20 mg MTX
responder rate · % of participants
No placebo or comparator arm
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
show 11 more results
41.4% (n=99) @ 26wk10 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
34% (n=100) @ 26wk5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
24.5% (n=98) @ 26wk2.5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
32.4% (n=68) @ 48wk*maximum tolerated dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 22 Participants as posted
39.4% (n=66) @ 48wk*reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 26 Participants as posted
13.25% (n=154) @ 24wklow dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
20.13% (n=155) @ 24wkhigh dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
65.4% (n=133) @ 52wk*
NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 87 participants as posted
0% (n=5) @ 52wk*
NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 0 participants as posted
32.8% (n=238) @ 520wk*
NCT00195650 · Phase 3 · registry result, not featured evidence · converted to % from 78 participants as posted
34.7% (n=516) @ 260wk*
NCT00195650 · Phase 3 · registry result, not featured evidence · converted to % from 179 participants as posted
HAQ-DI Less Than 0.5 58.8% (n=68) @ 48wkmaximum tolerated dose
event count · % of participants
No placebo or comparator arm
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 40 Participants as posted
show 1 more result
62.1% (n=66) @ 48wk*reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 41 Participants as posted
mTSS no Progression 66.2% (n=68) @ 48wkmaximum tolerated dose
event count · % of participants
No placebo or comparator arm
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 45 Participants as posted
show 1 more result
62.1% (n=66) @ 48wk*reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 41 Participants as posted
Time to Flare NA vs NA placebo months
time to event · months
NCT02198651 · Phase 4 · registry result, not featured evidence

+ 236 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab's landscape · adalimumab-adbm (Cyltezo)'s landscape